Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review ArticleReview

MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models

ULRICH H. WEIDLE and ADAM NOPORA
Cancer Genomics & Proteomics March 2022, 19 (2) 113-129; DOI: https://doi.org/10.21873/cgp.20308
ULRICH H. WEIDLE
Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adam.nopora@roche.com
ADAM NOPORA
Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: weidle49@t-online.de
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Squamous cell carcinoma of the esophagus is associated with a dismal prognosis. Therefore, identification of new targets and implementation of new treatment modalities are issues of paramount importance. Based on a survey of the literature, we identified microRNAs conferring antitumoral activity in preclinical in vivo experiments. In the category of miRs targeting secreted factors and transmembrane receptors, four miRs were up-regulated and 10 were down-regulated compared with five out of nine in the category transcription factors, and six miRs were down-regulated in the category enzymes, including metabolic enzymes. The down-regulated miRs have targets which can be inhibited by small molecules or antibody-related entities, or re-expressed by reconstitution therapy. Up-regulated miRs have targets which can be reconstituted with small molecules or inhibited with antagomirs.

Key Words:
  • miR-based target identification
  • miR-related treatment modalities
  • preclinical in vivo models
  • squamous cell esophageal cancer
  • review

More than 450,000 patients are affected by esophageal cancer worldwide (1). The highest incidence is found in eastern Asia, eastern and southern Africa, and southern Europe (1). In the USA, the disease claimed 16, 170 deaths in 2020 (2). Esophageal cancer is one of the most lethal types of cancer and surgical resection, chemotherapy and radiotherapy are primary treatments but have limited efficacy and severe side-effects (3). Two histological subtypes have been identified: esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) as epidemiologically and biologically distinct types of cancer (4). ESCC is the major histological subtype and accounts for 80% of esophageal cancer worldwide (4). However, the incidence of esophageal adenocarcinoma and ESCC vary with geographic location (4). Barrett’s esophagus is a benign precursor lesion of esophageal adenocarcinoma (5).

Characterization of the genomic landscape of ESCC has revealed heterogeneity, and mutations in pathways of growth factor receptors, cell-cycle regulation, apoptosis, angiogenesis and DNA repair (6, 7). The US Food and Drug Administration recently approved pembrolizumab and nivolumab, which both target programmed death 1 for immunotherapeutic intervention for advanced ESCC. Pembrolizumab was approved for treatment of unresectable/metastatic tumors with high microsatellite instability, and nivolumab for unresectable, advanced or recurrent tumors (8, 9). Nevertheless, there is an urgent need to identify new targets and treatment modalities for ESCC. In this review, we focus on microRNAs (miRs) shown to be ESCC-related in preclinical in vivo systems for target identification and as new treatment modalities through inhibition or reconstitution of function for ESCC.

MicroRNAs and Cancer

miRs are small regulatory RNAs that derive from hairpin regions of precursor transcripts (10). Each miR associates with an Argonaute protein, forming a silencing complex which binds to complementary sequences of target transcripts and promotes destabilization or translational repression of the bound transcripts (10). miRs can interfere with several targets and act as oncogenes or tumor suppressors in a context-dependent manner (11, 12). They play a role in all aspects of cancer such as proliferation, apoptosis, invasion, metastasis and angiogenesis (13-16). In proof-of-concept experiments it has been shown that deletion of miR-15 and miR-16 induced B-cell lymphoma in mice by targeting BCL2 apoptosis regulator (BCL2) (17) and expression of miR-17 in the liver of transgenic mice caused hepatocellular carcinoma (18). The roles of miRs in ESCC have been summarized in several reviews (19-21). In this review, we focus on miRs in preclinical in vivo ESCC models in order to identify targets for therapeutic intervention and to explore new entities for therapeutic intervention by inhibition of deregulated miRs or replacement therapy with miR mimics.

miRs Targeting Secreted Factors and Transmembrane Receptors in In Vivo Models

Up-regulated miRs (Figure 1A).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Up-regulated (A) and down-regulated (B) miRs targeting secreted factors and transmembrane receptors in esophageal cancer cells in preclinical in vivo systems. ADAMTS1: A disintegin and metalloprotease with thrombospondin motifs 1; CD44, 47, 133: cluster of differentiation 44, 47, 133; EGFR: epidermal growth factor receptor; EI24: etoposide-induced 2.4 transcript; HER2: human epidermal growth factor receptor 2; IGF1R: insulin growth factor-like receptor 1; INTα6: integrin α6; INTβ6: integrin β6; INV: invasion; MET: metastasis; PROL: proliferation; RAGE: receptor for advanced glycation end-products; SARA: SMAD anchor for receptor activation; TG: tumor growth; TGFβR2: transforming growth factor receptor 2; TNFα: tumor necrosis factor α; VEGFA: vascular endothelial growth factor A.

miR-19a [targeting tumor necrosis factor α (TNFα)]. miR-19a induced proliferation of ESCC cell lines EC109, EC 9706 and KYSE150 (22). An antisense oligo directed against miR-19a induced apoptosis in EC9706 cells (22). Knockdown of miR-19a inhibited in vivo tumorigenicity of EC9706 cells in nude mice (22). TNFα was identified as a direct target of miR-19a (22). Pro- and anti-tumoral effects, such as stimulation of cancer progression and metastasis, direct cytotoxicity to tumor cells and stimulation of the immune response against cancer, have been reported (23-26). Therefore, the tumor-inhibitory function of TNFα in ESCC has to be resolved in more detail.

miR-25 (targeting E-cadherin). Overexpression of miR-25 in patients with ESCC was associated with lymph node metastasis and poor survival (27). miR-25 induced migration but not proliferation in KYSE150 ESCCs (27). Targeting miR-25 reversed epithelial–mesenchymal transition (EMT) transition in ESCCs in vitro (27). E-Cadherin was identified as a direct target of miR-25 (27). Up-regulation of miR-25 induced lung metastases after tail vein injection of EC-109 ESCC cells in immunocompromised mice (27). Down-regulation of E-cadherin was correlated with development and progression of cancer, high tumor grade and low patient survival (28, 29). It has been shown that modulation of expression of E-cadherin promotes migration of ESCC cells (30). However, due to specificity issues inherent to up-regulation of E-cadherin with small molecules, targeting E-cadherin is a difficult issue from a drug-discovery point of view.

miR-483-3p [targeting etoposide-induced 2.4 transcript (EI24)]. miR-483-3p was overexpressed in ESCC, promoted proliferation, G1/G2 transition and migration of ESCCs, and inhibited sensitivity of ESCC to chemotherapy (31). miR-483-3p promoted growth of ESCC xenografts in immunocompromised mice (31). EI24 has been identified as a direct target of miR-483-3p (31). EI24, a p53-response protein, contains six transmembrane domains and suppresses cell growth through caspase 9 and mitochondrial pathways including in ESCC (32, 33). Furthermore, EI24 has been shown to contribute to EMT (34).

miR-584k [targeting A disentegrin and metalloprotease with thrombospondin motifs 1 (ADAMTS1)]. miR-548k overexpression correlated with poor prognosis of patients with ESCC (35). miR-548k mediated proliferation and cell-cycle progression of KYSE30 and KYSE510 ESCCs and induced migration and tube formation by human dermal lymphatic endothelial cells (35). In nude mice implanted with KYSE30-derived ESCCs transfected with miR-548k, lymphangiogenesis, increased microlymphatic density and metastasis to lymph nodes were observed (35). Tail vein injection experiments indicated that miR-548k promotes lung metastasis (35). ADAMTS1 was identified as a target of miR-548 (35, 36). Overexpression of miR-548k promoted tyrosine phosphorylation in dermal lymphatic endothelial cells (35). Vascular endothelial growth factor receptor 3 (VEGFR3), a stimulator of lymphangiogenesis and promoter of lymphatic metastasis, is stimulated by ADAMTS1 (36-39). miR-548k also down-regulates Kruppel-like factor 10 (KLF10), a repressor of epidermal growth factor receptor (EGFR) (40).

Down-regulated miRs (Figure 1B).

miR-126 (targeting VEGFA). Lower expression of miR-126 in ESCC tissues and cell lines compared to corresponding normal tissues was observed (41). VEGFA was identified as a target of miR-126 (41). miR-126 inhibited proliferation of JH-Eso Ad1, OE19 and OE33 ESCC cells (41). In nude mice, tumor growth was inhibited in OE33 cells transfected with miR-126 (41). VEGFA can increase permeabilization of blood vessels and growth of new blood vessels (42, 43). Targeting of VEGFA with monoclonal antibodies has been pursued successfully in clinical trials, leading to approval for several tumor indications, but not ESCC (44).

miR-133b (targeting EGFR). miR-133b repressed proliferation, apoptosis, anchorage-independent growth and EMT of KYSE150 and ECA109 ESCCs and its expression was reduced in ESCC tissues (45). miR-133b inhibited tumor growth and lung metastases of KYSE150 and ECA109 ESCCs in nude mice (45). EGFR was identified as a target of miR-133b (45). miR-133b was shown to inhibit anchorage-independent growth, migration and invasion of ESCC via integrin β4 (INTB4)/focal kinase/growth-factor receptor bound protein 2, AKT serine/threonine kinase 1 and extracellular signal-regulated kinase signaling pathways (45). Gene amplification, aberrant activation and activation mutations of EGFR have been observed in several types of cancer (46, 47). EGFR has been identified as an important target for ESCC (48): 70-88% of patients with ESCC show high expression of EGFR and its high expression correlates with poor prognosis (49, 50).

miR-193a-5p [targeting human epidermal growth factor receptor 2 (HER2)]. miR-193a-5p inhibited HER2 expression and enhanced radiosensitivity of ESCCs in vitro and in vivo in mice (51). It reduced colony formation in KYSE70 and KYSE510 ESCCs and inhibited tumor growth by down-regulation of HER2 in vitro and in vivo (51). High expression of miR-193a-5p was correlated with successful chemoradiation treatment of ESCC (51). HER2 was also targeted in an orthotopic model of esophageal carcinoma (52). HER2 is up-regulated in 10-20% of ESCC and its up-regulation is correlated with worse prognosis (53-56).

miR-375 [targeting insulin-growth factor like 1 receptor (IGF1R)]. Down-regulation of miR-375 correlated with advanced stage, distant metastasis, poor overall survival and disease-free survival in patients with ESCC (57). Down-regulation of miR-375 in ESCC was due to promoter methylation (57). IGFR1 has been identified as a direct target of miR-375 (57). miR-375 suppressed proliferation and invasion of KYSE10 and KYSE30 ESCCs and their metastasis to the liver after tail vein injection into nude mice (57). In clinical specimens of ESCC, IGF1R expression was negatively correlated with miR-375 expression (57). Targeting of the IGF1R pathway has been pursued in many types of cancer (58). In ESCC, overexpression of IGF1R was noted in 60% of tumors in patients (59). IGF1R is a marker for prognosis and a potential therapeutic target for ESCC (60, 61). The IGF1R pathway has been identified as a key axis in progression of ESCC (62). Antitumoral effects have been observed with figitumumab, a monoclonal antibody directed against IGF1R in several preclinical in vitro and in vivo models of ESCC (63).

miR-17/20a [targeting transforming growth factor β receptor 2 (TGFRβ2) and SMAD anchor for receptor activation (SARA)]. Down-regulation of miR-17/20a correlated with ESCC lymph node metastasis and inhibited migration and invasion of 30D and 180-U ESCCs (64). miR-17/20a suppressed lung metastasis of 30D cells after tail vein injection into nude mice (64). miR-17/20a did not influence proliferation and apoptosis of ESCCs (64). TGFRβ2 and SARA were identified as bona fide targets of miR-17/20a (64). A heterotrimeric SMAD2, -3, -4 complex is translocated into the nucleus to regulate transcription of genes such as INTB6, which mediates migration and invasion (64, 65). The other target of miR-17/20a, SARA, recruits SMAD2/SMAD3 complexes to TGFRβ2 at intracellular membranes (66). However, TGFβ signaling can exert pro- as well as antitumoral effects in a context-dependent manner and therefore has to be investigated in further detail in ESCC (67, 68).

miR-92b (targeting INTαv). miR-92b inhibited lymph node metastasis and was associated with favorable prognosis in patients with ESCC (69). miR-92b inhibited migration and invasion of 30D ESCCs in vitro (69). In vivo, miR-92b inhibited invasion into the peri-esophageal muscle after orthotopic implantation of 30D cells into nude mice (69). In the tail vein injection model, miR-92b inhibited lung metastasis (69). INTαv has been identified as a bone fide target of miR-92b (69). Furthermore, miR-92b reduced phosphorylation of focal adhesion kinase and reduced activation of RAS-related C3 botulinum toxin substrate (RAC1), both essential mediators of cellular motility in ESCCs (69, 70). Integrins consist of 18α and 8β transmembrane receptors, inclusive 24 heterodimers, which can cross-link components of the extracellular matrix with the cytoskeleton and thus have an impact on invasion and metastasis of tumor cells (71, 72).

miR-34a [targeting cluster of differentiation 44 CD44)]. miR-34a was down-regulated in ESSC tissues and cell lines and inhibited invasion and migration of ECA109 and TE-13 ESCC cells (73). miR-34 inhibited tumor growth and metastasis in nude mice (73). CD44 was identified as a target of miR-34a (73). CD44 is a transmembrane protein with hyaluronic acid as the major ligand, resulting in activation of pathways involved in proliferation, survival, cytoskeletal changes, motility and metastasis (74, 75). CD44 standard form and several splice variants which contain additional peptide motifs that can interact with growth factors and cytokines at the cell surface may play a role in EMT and adaptive plasticity of cancer cells (76, 77). It has been shown that up-regulation of CD44 in E-cadherin-negative esophageal cancer cells results in activation of invasion (78). Tumor-initiating cells in ESCC express high levels of CD44 (79) and overexpression of CD44 is associated with poor prognosis in patients with ESCC (80).

miR-133a (targeting CD47). CD47 expression in ESCC was associated with lymph node metastasis (81). Expression of CD47 was significantly lower in ESCC samples in comparison to corresponding non-cancerous tissues (81). CD47 was identified as a target of miR-133a (81). Pre-miR 133a strongly inhibited the tumorigenic potential of TE-8 ESCC in vivo in nude mice (81). CD47 is a transmembrane molecule which inhibits phagocytosis and therefore is a target which has received much attention in translational oncology (82-84). It was shown that following blocking of CD47 with monoclonal antibodies, ESCCs were phagocytosed by M2 macrophages (85).

miR-377 (targeting CD133 and VEGF). Down-regulation of miR-377 correlated with poor chemotherapy response and poor survival in patients with ESCC (86). miR-377 inhibited tumor-initiating cell properties (86). CD133 and VEGF were identified as direct targets of miR-377 (86). In the tail vein injection model, miR-377 inhibited lung colonization of KYSE270 cells in mice (86). A systemic formulation of a miR-377 mimic inhibited tumor growth, angiogenesis and metastasis of ESCC cells in nude mice (86). CD133 is a marker of tumor-initiating cells in cancer, but its quantitation has been hampered by the inability of current antibodies to detect CD133 variants and deglycosylated epitopes (87, 88). CD133 is a regulator of metastasis through cancer stem cells (89). CD133 promotes stemness in ESCC cells and its higher expression is associated with lymph node metastasis, clinical stage and histopathological grade of ESCC (90, 91). As outlined previously, VEGFA is a validated target for several types of cancer (42).

miR-185 [targeting receptor for advanced glycation end-products (RAGE)]. Overexpression of miR-185 suppressed migration and invasion of TE-11 and ECA109 ESCCs in vitro (92). In the tail vein metastasis model, miR-185 suppressed metastasis of ECA109 cells (92). In patients with ESCC, the level of plasma miR-185 was found to be decreased (92). RAGE was identified as a target of miR-185 (92). RAGE, a 35-kDa transmembrane receptor of the immuno-globulin super-family, and its ligands, high motility group box 1 (HMGB1) and S100 group of proteins, release cytokines after their interaction. Transcription factors which are involved in TG and survival, EMT and metastasis are also activated. RAGE is being evaluated as a target forcancer therapy (93, 94). Expression levels of RAGE are related to poor prognosis in patients with ESCC (95).

miRs Targeting Transcription Factors

Up-regulated miRs (Figure 2A).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Up-regulated (A) and down-regulated (B) miRs targeting transcription factors in esophageal cancer cells in preclinical in vivo systems. AKT: Serine-threonine kinase AKT; ARID3A: AT-rich interactive domain-containing protein 3A; CXX5: CCX-type zinc finger protein 5; DDP res: cisplatin resistance; EMT: epithelial–mesenchymal transition; FOXK2: forkhead box protein K2; FOXO31: forkhead-box protein 31; FOXM1: forkhead box protein M1; GSK3β: glycogen synthase kinase 3β; INV: invasion; KLF4: Krüppel-like factor 4; MAPK: mitogen-activated protein kinase; MET: metastasis; MYC: transcription factor MYC; mTOR: mechanistic target of rapamycin; p38: mitogen-activated protein kinase p38; PITX2: paired-like homeodomain transcription factor 2; PPARγ: peroxisome proliferator-activated receptor γ; PROL: proliferation; SMAD4: signaling protein SMAD4; SNAI2: snail family transcriptional repressor 2; SOX4: sex determining region Y-box 4; STAT3: signal transducer and activator of transcription 3; TG: tumor growth; ZEB1: zinc finger E-box binding homeobox 2.

miR-7-5p [targeting Kruppel-like factor 4 (KLF4)]. miR-7-5p was up-regulated in ESCC tissues and inhibited proliferation of ECA109 and TE-9 ESCCs (96). A miR-7-5p antagonist induced apoptosis in ECA109 and TE-9 cells and suppressed migration and invasion of ECA109 cells (96). A miR-7-5p antagonist inhibited tumor growth of ECA109 cells in vivo (96). KLF4 was identified as a direct target of miR-7-5p (96). KLF4 is a member of the KLF family of zinc finger transcription factors and contains three C2H2 zinc fingers. KLF4 is a stem cell factor which, together with octamer-binding transcription factor 4, SOX2, homeobox protein NANOG and transcription factor MYC, is involved in the induction of pluripotent stem cells (97). Most studies suggest that KLF4 acts as a tumor suppressor, but pro-tumorigenic activity of KLF4 has also been reported (98). KLF4 promoted ESCC differentiation by up-regulation of keratin 13 expression (99). In ESCC, KLF4 was shown to act as a tumor suppressor and was correlated with good prognosis (100).

miR-10b [targeting peroxisome proliferator-activated receptor gamma (PPARγ)]. miR-10b was up-regulated in patients with ESCC and targeted PPARγ (101). Suppression of miR-10b in ESCC cell lines enhanced chemosensitivity to cisplatin in vitro and in vivo (101). PPARγ enhanced resistance to cisplatin by activating AKT/mechanistic target of rapamycin (mTOR)/ribosomal protein70 S6 kinase (p70S6K) signaling (101). PPARγ is a member of the nuclear receptor superfamily and was shown to act as a ligand-inducible transcription factor which can exert tumor-suppressive and pro-tumorigenic effects (102, 103). It has been shown that PPARγ ligands suppress proliferation and induce apoptosis of ESCCs by inhibiting toll-like receptor 4-dependent mitogen-activated protein kinase signaling (104). Reduced PPARγ expression is correlated with poor prognosis in patients with ESCC (105).

miR-32 (targeting CXXC5-type zinc finger protein 5). Increased expression of miR-32 has been noted in ESCC tissues and cells (106). Down-regulation of miR-32 inhibited migration and invasion of EC9706 and KYSE450 ESCCs (106). In vivo, miR-32 inhibitors reduce tumor weight and number of metastatic nodules (106). CXXC5-type zinc finger protein 5 (CXXC5) was identified as a target of miR-32 (85). miR-32 inhibitors reduced migration, invasion, EMT and TGFβ signaling (106). CXXC5 inhibited WNT/βcatenin signaling, induced apoptosis by stimulating TGFβ/SMAD signaling and activated DNA repair via the serine-threonine kinase ataxic telangiectasia mutated/p53 pathway (107-109). In addition, CXXC5 promoted TGFβ induced cell-cycle arrest (110). The role of CXXC5 in ESCC remains to be resolved in further detail.

miR-99b/let7a/miR-125a [targeting AT-rich interaction domain 3A (ARID3A)]. The miR-99b/let7a/miR-125a cluster promoted ESCC migration and invasion in vitro and induced experimental metastases in vivo (111). Transcription factor zinc finger E-box binding homeobox factor 1 (ZEB1) bound to the promoter of this cluster and regulated its transcription (111). ARID3A was identified as a direct target of miR-99b/let7a/miR-125a (111). ARID3A is a transcription factor which regulates chromatin accessibility, proliferation, differentiation and is critical for B-cell development (112). ARID3A expression was found to be reduced in ESCC compared to normal corresponding tissues (113). ARID3A has been shown to be involved in carcinogenesis and development of ESCC (114).

miR-602 [targeting forkhead box protein K2 (FOXK2)]. miR-602 was increased in ESSC tissues and its expression level significantly correlated with poor survival (115). DNA hypomethylation was involved in increased expression of miR-602 in ESCC (115). miR-602 promoted proliferation, colony formation, migration and invasion by KYSE 150 and KYSE 450 ESCCs (115). In KYSE 450 cells transfected with miR-602, tumor growth was significantly accelerated (115). miR-602 antagomir directly injected into the tumor led to slower tumor growth (115). In the tail vein assay, miR-602 induced increased metastasis to the lungs, to liver, bones and adrenal glands (115). FOXK2 was identified as a target of miR-602 (116). FOXK2 binds to purine-rich motifs on DNA and is involved in proliferation, survival, DNA damage, metabolism, invasion, migration and metastasis. However, the function of FOXK2 is context-dependent and depends on the tumor type (117). Down-regulation of FOXK2 was associated with poor prognosis in patients with gastric cancer (118).

Down-regulated miRs (Figure 2B).

miR-124 [targeting signal transducer and activator of transcription 3 (STAT3)]. miR-124 was suppressed in ESCC tissues and cell lines, inhibited proliferation and migration and induced apoptosis in ECA190 and TE-1 ESCCs (119). In ECA109 engrafted tumors, miR-124 inhibited growth (119). STAT3 was identified as a direct target of miR-124 (119). Activation of STAT3 by phosphorylation leads to its dimer formation, translocation into the nucleus, recognition of STAT3 binding elements and transcriptional activation of target genes. STAT3 regulates expression of genes related to the cell cycle, survival and the immune response, and is associated with progression and malignancy in several types of cancer (120, 121). STAT3 is being evaluated as a potential target for treatment of cancer (122). It has been shown that STAT3 is constitutively activated in ESCC tissues (123), inhibits apoptosis (124) and mediates proliferation and migration of ESCCs (125).

miR-130-3p (targeting SMAD4). miR-130a-3p directly targeted SMAD4 in EC-1 ESCCs (126). miR-130a-3p inhibited tumor axillary lymph node metastasis in nude mice (126). miR-130a-3p inhibited EMT, invasion, and migration induced by TGFβ in EC-1 cells (126). Restoration of SMAD4 expression rescued miR-130a-3p-suppressed EMT, invasion and migration (126). SMAD4 forms heterotrimeric complexes with SMAD2 and SMAD3 which are translocated into the nucleus and regulate expression of selected genes (127). SMAD4 is required for TGFβ-induced EMT (128). In healthy and early-stage cancer cells, TGFβ signaling has tumor-suppressive functions; in late-stage cancer, it can promote tumor progression, metastasis and chemotherapy resistance (129, 130).

miR-133a (targeting SOX4). miR-133a was down-regulated in ESCC tissues and cell lines KYSE150, KYSE510, EC9706 and TE13 in comparison to SHEE non-transformed esophageal cell line (131). miR-133a inhibited proliferation, migration and invasion of ESCCs as mentioned above (131). In vivo, miR-133a inhibited tumorigenicity of TE13 cells in a mouse xenograft model (131). SOX4 was identified as a direct target of miR-133a (131). SOX4 levels inversely correlated with miR-133a in ESCC tissues (131). SOX4 is up-regulated in many types of cancer and contributes to cellular transformation, cell survival and metastasis (132, 133). SOX4 was found to induce WNT signaling and EMT (134, 135). The role of SOX4 in ESCC remains to be explored in further detail.

miR-145 (targeting MYC). miR-145 was down-regulated in ESCC tissues and suppressed proliferation, invasion and tumor growth of ESCC xenografts by targeting MYC (136). MYC is a transcription factor which increases proliferation, cell-growth and inactivates cell-cycle inhibitors (137-139). MYC can be amplified in ESCC and its high expression is significantly correlated with poor prognosis in patients with ESCC (140, 141). Compounds identified by several MYC inhibition approaches are close to clinical trials (142).

miR-150 (targeting ZEB1). Low expression of miR-150 contributed to malignant potential, lymph node metastasis, lymphatic and venous invasion, clinical staging and poor prognosis of patients with ESCC (143). miR-150 inhibited proliferation, migration and regulated morphology of TE-8 ESCCs (143). In a TE-8 xenograft model, miR-150 inhibited tumor growth (143). ZEB1 was identified as a target of miR-150 (143). ZEB1 contains seven zinc-fingers and one homeodomain and is a transcription factor that controls EMT (144). Aberrant expression of ZEB1 fosters invasion, migration and metastasis (145). It has been shown that ZEB1 promotes invasiveness of ESCC and confers an unfavorable prognosis in patients with ESCC (146).

miR-204 (targeting FOXM1). miR-204 was down-regulated in ESCC tissues in comparison to corresponding normal tissues (147). miR-204 inversely regulated EMT in EC109 and TE10 ESCCs (147). Overexpression of miR-204 suppressed growth of EC109 cells in vivo (147). FOXM1 was identified as a direct target of miR-204 (147). FOXM1 is a member of the family of FOXO transcription factors which are deregulated in many diseases, including cancer (148). FOXM1 is required for proliferation of many normal cells and as a master regulator is implicated in all hallmarks of cancer (149). FOXM1 is overexpressed in many types of tumors. Its oncogenic role is mediated by interaction with β-catenin and SMADs to induce WNT and TGFβ signaling pathways (150). Silencing of FOXM1 inhibited proliferation and migration of ESCCs (151). In ESCC, FOXM1 can activate phosphoinosite-3 kinase (PI3K)/AKT signaling and its expression was correlated with poor prognosis (151).

miR-507 [targeting nuclear factor erythroid 2-related factor 2 (NRF2)]. Administration of miR-507 alone or in combination with cisplatin inhibited tumor growth in vivo (152). NRF2, a basic leucine zipper protein transcription factor, was identified as a target of miR-507 (153). Under high oxidative stress levels, the NRF2 pathway is activated. Normally, NRF2 is degraded by Kelch-like-ECH-associated protein (KEAP1) and Cullin3 through ubiquitinylation. Non-ubiquitinylated NRF2 is translocated into the nucleus, combines with musculoaponeurotic fibrosarcoma transcription factors and binds to anti-oxidative response elements in the promoter regions of anti-oxidative stress genes (153). Tumor-suppressive as well as oncogenic functions have been assigned to NRF2 (154-156). In NRF2-addicted cancer, NRF2 is constitutively activated due to somatic mutations in KEAP1 or NRF2 and other mechanisms that disrupt binding of KEAP1 to NRF2 (157). In ESCC, NRF2 has been shown to induce proliferation and to be associated with radio- and chemotherapy resistance (158, 159).

miR-630 [targeting snail family transcriptional repressor 2 (SNAI2)]. Reduced miR-630 expression was associated with poor survival in patients with ESCC (160, 161). Transcription factor SNAI2, also known as SLUG, has been identified as a direct target of miR-630 (160). Ectopic expression of miR-630 inhibited proliferation, invasion, EMT and metastasis of ESCC cell lines in vitro and in vivo. SNAI2 plays a role in EMT and mediates anti-apoptotic activity (162, 163). Independently it has been shown that its down-regulation by RNA interference inhibited invasion and growth of ESCC (164).

miR-664a [targeting paired-like homeodomain transcription factor 2 (PITX2)]. Low expression of miR-664a correlated with tumor recurrence or metastasis in patient samples (165). miR-664a overexpression in KYSE-140 and -109 ESCCs reduced cell growth, colony formation, migration and invasion in vitro (165). Tumor growth in vivo was inhibited by miR-664 in KYSE-140 and ECA109 cells in immunocompromised mice (165). The number and size of lung metastases of these cell lines in mice were dramatically reduced by miR-664 (165). PITX2 was identified as a direct target of miR-664a (165). miR-664a was down-regulated by promoter hypermethylation and inhibited the WNT/β catenin pathway by targeting PITX2 in ESCCs (165). PITX2 acts as a transcription factor and participates in muscle formation (166, 167). Up-regulation of miR-664a reduced ESCC cell stem-like traits (168).

miRs Targeting Metabolic Enzymes (Figure 3)

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Down-regulated miRs targeting enzymes in esophageal cancer cells mediating efficacy in preclinical in vivo systems DNA polβ: DNA polymerase β; LDHB: lactate dehydrogenase B; MET: metastasis; MTDH1: metadherin 1; OGT: O-linked-N-acetylglucosaminacetylation transferase; PROL: proliferation; PSAT1: phosphoserine aminotransferase 1; INV: invasion; TG: tumor growth; TIGAR: p53-inducible glycolysis and apoptosis regulator; USP26: ubiquitin-specific protease 26.

miR-144 [targeting p53-inducible glycolysis and apoptosis regulator (TIGAR)]. miR-144 was down-regulated in patients with ESCC and correlated with poor prognosis (169). Proliferation of EC9706 and ECA109 ESCCs was inhibited by miR-144, which was associated with a pro-apoptotic effect (169). In vivo, miR-144 inhibited tumor growth of xenografts of these cell lines (169). TIGAR was identified as a direct target of miR-144 (169). TIGAR acts as a fructose-2,6 biphosphatase and as a regulator of glucose breakdown (170). In some types of cancer, TIGAR is aberrantly up-regulated and promotes carcinoma growth by metabolic intermediates derived from the pentose phosphate pathway (171). TIGAR also reprograms glucose metabolism from glycolysis to the glutamine pathway through AMP-activated kinase (171). In TIGAR-overexpressing xenografts and patient-derived xenografts, efficacy was significantly enhanced when a glutaminase inhibitor was combined with chemotherapy agents (172).

miR-203a-5p [targeting ubiquitin-specific peptidase 26 (USP26)]. miR-203-5p was significantly down-regulated in esophageal tumor tissue (173). Overexpression of miR-203a-5p inhibited invasion and migration of KYSE150 and TE-1 ESCCs (173). Nude mice injected with a miR-203-5p mimic showed reduced lung metastasis of KYSE150 cells after tail vein injection (173). miR-203a-5p targets USP26 which stabilizes EMT-related transcription factor SNAI1 (173). In normal tissues, USP26 is exclusively expressed in testis (174). USPs are critical for cancer progression and several approaches to develop inhibitors of USPs for treatment of cancer are being pursued (175-177). It was shown that USP26 promotes ESCC by stabilizing SNAI1 (178).

miR-340 and miR-365 [targeting phosphoserine aminotransferase 1 (PSAT1)]. Both these miRs were down-regulated in ESCC cell lines EC1, EC109, EC9706 and in ESCC tissues (179, 180). Both inhibited invasion of EC9706 and EC109 ESCCs (179, 180). miR-340 as well as miR-365 transfectants reduced growth of EC9706 xenografts in nude mice (179, 180). miR-340 and miR-365 inhibited EMT by up-regulation of E-cadherin, down-regulation of SNAI1 and vimentin, and reduction of phosphorylated glycogen synthase kinase 3β (179, 180). PSAT1, involved in serine biosynthesis, is amplified in a significant subset of tumors and RNAi directed against PSAT1 reduced cancer cell survival and growth; therefore, discovery of PSAT1 inhibitors as anticancer agents is being pursued (181). PSAT1 plays a crucial role in development of ESCC and its expression predicts poor survival (182).

miR-375 [targeting lactate dehydrogenase B and metadherin (MTDH)]. miR-375 was down-regulated in ESCC clinical specimens in comparison to neighboring normal tissue sections, and a low level of miR-375 was associated with poor prognosis (183). miR-375 inhibited proliferation and migration of TE2 and T.Tn ESCCs (183). Lactate dehydrogenase B (LDHB) and MTDH were identified as direct targets of miR-375 (183). A miR-375/atelocollagen complex administered subcutaneously suppressed growth of TE2 and T.Tn xenografts in nude mice (184). miR-375 target LDHB converts lactose to pyruvate, which is further oxidized and is critical for mTOR-mediated tumorigenesis (185). LDHB also controls apoptosis and autophagy in tumor cells (186). The other miR-375 target, MTDH, functions as a regulator of EMT in carcinomas (187). It plays a role in tumor progression, invasion, resistance to chemotherapy in many carcinomas including ESCC. MTDH is required for proliferation, migration and invasion of ESCC (188, 189).

miR-485-5p [targeting O-linked N-acetylglucosamine transferase (OGT)]. miR-485-5p was expressed at low levels in ESCC cell lines and inhibited cell proliferation, migration and invasion in TE-1 and ECA109 ESCCs (190). Tumor growth in nude mice was inhibited in TE-1 cells overexpressing miR-485-5p (190). OGT was identified as a direct target of miR-485-5p (190). OGT catalyzes addition of N-acetylglucosamine through O-glycosidic linkage to serine or threonine and an S-glycosidic linkage to cysteine (191, 192). OGT is aberrantly expressed in cancer and modifies signaling proteins, transcription factors, metabolic enzymes, histones and chromatin regulators (193).

miR-499 (targeting DNA polymerase β). DNA polymerase β has been identified as the target of miR-499 in EC9706 and KYSE30 ESCCs (194). miR-499 inhibited proliferation, induced apoptosis and reduced the DNA-repair capacity of EC9706 and KYSE30 ESCCs by targeting DNA polymerase β (194). miR-499 also inhibited tumor growth of xenografts derived from these cell lines in nude mice (194). DNA polymerase β is essential for short-patch base excision repair. DNA polymerase β overexpression resulted in aneuploidy and tumorigenesis in nude immunodeficient mice (195, 196). Targeting DNA polymerase β is considered as an option for cancer therapy (197).

Additional Targets

In addition miR-34a and miR-133b should be mentioned. They target phospholipase epsilon 1 (PLCE1) (198) and squalene epoxidase (SQE) (199), respectively. SQE is a rate-limiting enzyme in cholesterol biosynthesis (199). In vivo activity in ESCC-related preclinical xenografts was demonstrated with the corresponding targets, not with miR-34a and miR-133b.

Concluding Remarks

Up-regulated miRs indicate targets which have to be reconstituted with low-molecular-weight compounds or inhibited by miR antagonists such as locked nucleic acids and antagomirs (200). All antagonists are oligonucleotides with sequences complementary to endogenous miRs (200-203). Down-regulated miRs identify targets which can be inhibited by small molecules or antibody-related moieties, or which can be re-expressed by replacement therapy with miR mimetics or vector-based expression (200-203). miR mimetics are double-stranded RNAs which reconstitute the function of the corresponding miRs.

When deregulated miRs were grouped into categories as secreted factors and transmembrane receptors, transcription factors and metabolic enzymes, for secreted factors and transmembrane receptors, four miRs were up-regulated and 10 were down-regulated in ESCC tissues in comparison to matching normal tissues (Figure 1). VEGF (miR-126), EGFR (miR-133b), HER2 (miR-193a), IGF1R (miR-375) and CD47 (133a) seem to be the most promising targets for inhibition with small molecules and biological agents or reconstitution of the corresponding miRs.

In the category of transcription factors, we identified five miRs up-regulated and nine down-regulated with efficacy in preclinical in vitro and in vivo systems (Figure 2). Drugs targeting transcription factors such as estrogen receptor and androgen receptor are among the most impactful drugs in oncology (5). STAT3 (miR-124), SMAD4 (miR-130-3p), SOX4 (miR-122a), MYC (miR-145), ZEB1 (miR-150), FOXM1 (miR-204), NRF2 (miR-507), SLUG (miR-630) and PITX2 (miR-664) have emerged as potential targets for inhibition at the protein level or reconstitution of the corresponding miRs. A subset of ESCCs is addicted to NRF2 this aspect is worth further detailed investigation (156). In general, targeting transcription factors is associated with technical issues of tractability with respect to inhibition and specificity, as well as toxicity issues. Inhibitory efforts may target protein–protein interactions with co-factors, inhibition of transcription factor DNA binding, inhibition of expression of regulators of transcription factors, altering levels of ubiquitinylation and subsequent proteolysis (204-208). Proteolysis targeting chimeras are under active investigation, as well as cysteine reactive inhibitors, which target intrinsically disordered domains of transcription factors (204-208).

Six miRs targeting enzymes were down-regulated (Figure 3). TIGAR (miR-144), PSAT1 (miR-340 and miR-365) and LDHB (miR-375) are metabolic enzymes. These targets and their corresponding miRs deserve further validation for treatment of ESCC. Transformed cells adopt metabolism and support tumor initiation and progression and therefore become addicted to these changes (209-211). Drugs targeting metabolic enzymes such as the dihydrofolate reductase inhibitor methotrexate and thymidylate inhibitor 5-fluorouracil are well established in cancer therapy.

Inhibition of miRs and replacement therapy face several technical problems which are not discussed in this review. Among these issues are: delivery of the agents to tumor tissues, optimization of their escape after internalization, inappropriate biodistribution and optimization of their pharmaco-kinetic and pharmaco-dynamic properties (211-213). Further critical issues are off-site effects and cytokine-release syndrome (213). Recently the field has witnessed several drawbacks (214). However, cobomarsen, an oligonucleotide-based inhibitor of miR-155, was shown to slow growth of diffuse large cell B-cell lymphoma xenografts without any toxic effects and is currently being evaluated in several clinical studies in patients with hematological malignancies and seems to be well tolerated (215, 216). Nevertheless, clinical proof-of-concept of miR-based therapies is still pending.

Footnotes

  • Authors’ Contributions

    AN and UHW jointly designed and prepared the article.

  • Conflicts of Interest

    AN is and UHW was an employee of Roche.

  • Received November 23, 2021.
  • Revision received January 17, 2022.
  • Accepted January 19, 2022.
  • Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Hull R,
    2. Mbele M,
    3. Makhafola T,
    4. Hicks C,
    5. Wang SM,
    6. Reis RM,
    7. Mehrotra R,
    8. Mkhize-Kwitshana Z,
    9. Hussain S,
    10. Kibiki G,
    11. Bates DO and
    12. Dlamini Z
    : A multinational review: Oesophageal cancer in low to middle-income countries. Oncol Lett 20(4): 42, 2020. PMID: 32802164. DOI: 10.3892/ol.2020.11902
    OpenUrlCrossRefPubMed
  2. ↵
    1. Siegel RL,
    2. Miller KD and
    3. Jemal A
    : Cancer statistics, 2020. CA Cancer J Clin 70(1): 7-30, 2020. PMID: 31912902. DOI: 10.3322/caac.21590
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lordick F and
    2. Janjigian YY
    : Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol 13(6): 348-360, 2016. PMID: 26925958. DOI: 10.1038/nrclinonc.2016.15
    OpenUrlCrossRefPubMed
  4. ↵
    1. Testa U,
    2. Castelli G and
    3. Pelosi E
    : Esophageal cancer: Genomic and molecular characterization, stem cell compartment and clonal evolution. Medicines (Basel) 4(3): 67, 2017. PMID: 28930282. DOI: 10.3390/medicines4030067
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bujanda DE and
    2. Hachem C
    : Barrett’s Esophagus. Mo Med 115(3): 211-213, 2018. PMID: 30228724.
    OpenUrlPubMed
  6. ↵
    1. Pusung M,
    2. Zeki S and
    3. Fitzgerald R
    : Genomics of esophageal cancer and biomarkers for early detection. Adv Exp Med Biol 908: 237-263, 2016. PMID: 27573775. DOI: 10.1007/978-3-319-41388-4_12
    OpenUrlCrossRefPubMed
  7. ↵
    1. Talukdar FR,
    2. di Pietro M,
    3. Secrier M,
    4. Moehler M,
    5. Goepfert K,
    6. Lima SSC,
    7. Pinto LFR,
    8. Hendricks D,
    9. Parker MI and
    10. Herceg Z
    : Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Ann NY Acad Sci 1434(1): 342-359, 2018. PMID: 29917250. DOI: 10.1111/nyas.13876
    OpenUrlCrossRefPubMed
  8. ↵
    1. Baba Y,
    2. Nomoto D,
    3. Okadome K,
    4. Ishimoto T,
    5. Iwatsuki M,
    6. Miyamoto Y,
    7. Yoshida N and
    8. Baba H
    : Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci 111(9): 3132-3141, 2020. PMID: 32579769. DOI: 10.1111/cas.14541
    OpenUrlCrossRefPubMed
  9. ↵
    1. Vivaldi C,
    2. Catanese S,
    3. Massa V,
    4. Pecora I,
    5. Salani F,
    6. Santi S,
    7. Lencioni M,
    8. Vasile E,
    9. Falcone A and
    10. Fornaro L
    : Immune checkpoint inhibitors in esophageal cancers: are we finally finding the right path in the mist? Int J Mol Sci 21(5): 1658, 2020. PMID: 32121290. DOI: 10.3390/ijms21051658
    OpenUrlCrossRefPubMed
  10. ↵
    1. McGeary SE,
    2. Lin KS,
    3. Shi CY,
    4. Pham TM,
    5. Bisaria N,
    6. Kelley GM and
    7. Bartel DP
    : The biochemical basis of microRNA targeting efficacy. Science 366(6472): eaav1741, 2019. PMID: 31806698. DOI: 10.1126/science.aav1741
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Garzon R,
    2. Calin GA and
    3. Croce CM
    : MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009. PMID: 19630570. DOI: 10.1146/annurev.med.59.053006.104707
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lee YS and
    2. Dutta A
    : MicroRNAs in cancer. Annu Rev Pathol 4: 199-227, 2009. PMID: 18817506. DOI: 10.1146/annurev.pathol.4.110807.092222
    OpenUrlCrossRefPubMed
  13. ↵
    1. Weidle UH,
    2. Schmid D,
    3. Birzele F and
    4. Brinkmann U
    : MicroRNAs involved in metastasis of hepatocellular carcinoma: Target candidates, functionality and efficacy in animal models and prognostic relevance. Cancer Genomics Proteomics 17(1): 1-21, 2020. PMID: 31882547. DOI: 10.21873/cgp.20163
    OpenUrlAbstract/FREE Full Text
    1. Weidle UH,
    2. Brinkmann U and
    3. Auslaender S
    : microRNAs and corresponding targets involved in metastasis of colorectal cancer in preclinical in vivo models. Cancer Genomics Proteomics 17(5): 453-468, 2020. PMID: 32859626. DOI: 10.21873/cgp.20204
    OpenUrlAbstract/FREE Full Text
    1. Weidle UH,
    2. Birzele F and
    3. Nopora A
    : microRNAs promoting growth of gastric cancer xenografts and correlation to clinical prognosis. Cancer Genomics Proteomics 18(1): 1-15, 2021. PMID: 33419892. DOI: 10.21873/cgp.20237
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Weidle UH and
    2. Nopora A
    : Identification of MicroRNAs with in vivo efficacy in multiple myeloma-related xenograft models. Cancer Genomics Proteomics 17(4): 321-334, 2020. PMID: 32576578. DOI: 10.21873/cgp.20192
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Cimmino A,
    2. Calin GA,
    3. Fabbri M,
    4. Iorio MV,
    5. Ferracin M,
    6. Shimizu M,
    7. Wojcik SE,
    8. Aqeilan RI,
    9. Zupo S,
    10. Dono M,
    11. Rassenti L,
    12. Alder H,
    13. Volinia S,
    14. Liu CG,
    15. Kipps TJ,
    16. Negrini M and
    17. Croce CM
    : miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102(39): 13944-13949, 2005. PMID: 16166262. DOI: 10.1073/pnas.0506654102
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Zhu H,
    2. Han C and
    3. Wu T
    : MiR-17-92 cluster promotes hepatocarcinogenesis. Carcinogenesis 36(10): 1213-1222, 2015. PMID: 26233958. DOI: 10.1093/carcin/bgv112
    OpenUrlCrossRefPubMed
  17. ↵
    1. He B,
    2. Yin B,
    3. Wang B,
    4. Xia Z,
    5. Chen C and
    6. Tang J
    : MicroRNAs in esophageal cancer (review). Mol Med Rep 6(3): 459-465, 2012. PMID: 22751839. DOI: 10.3892/mmr.2012.975
    OpenUrlCrossRefPubMed
    1. Dias F,
    2. Morais M,
    3. Teixeira AL and
    4. Medeiros R
    : Involving the microRNA targetome in esophageal-cancer development and behavior. Cancers (Basel) 10(10): 381, 2018. PMID: 30322005. DOI: 10.3390/cancers10100381
    OpenUrlCrossRefPubMed
  18. ↵
    1. Li X,
    2. Wainscott C and
    3. Xi Y
    : MicroRNA provides insight into understanding esophageal cancer. Thorac Cancer 2(4): 134-142, 2011. PMID: 27755846. DOI: 10.1111/j.1759-7714.2011.00059.x
    OpenUrlCrossRefPubMed
  19. ↵
    1. Liu M,
    2. Wang Z,
    3. Yang S,
    4. Zhang W,
    5. He S,
    6. Hu C,
    7. Zhu H,
    8. Quan L,
    9. Bai J and
    10. Xu N
    : TNF-α is a novel target of miR-19a. Int J Oncol 38(4): 1013-1022, 2011. PMID: 21271217. DOI: 10.3892/ijo.2011.924
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wajant H
    : The role of TNF in cancer. Results Probl Cell Differ 49: 1-15, 2009. PMID: 19137269. DOI: 10.1007/400_2008_26
    OpenUrlCrossRefPubMed
    1. Ham B,
    2. Fernandez MC,
    3. D’Costa Z and
    4. Brodt P
    : The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res 11(1): 1-27, 2016. PMID: 27928197.
    OpenUrlPubMed
    1. Balkwill F
    : TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25(3): 409-416, 2006. PMID: 16951987. DOI: 10.1007/s10555-006-9005-3
    OpenUrlCrossRefPubMed
  21. ↵
    1. Josephs SF,
    2. Ichim TE,
    3. Prince SM,
    4. Kesari S,
    5. Marincola FM,
    6. Escobedo AR and
    7. Jafri A
    : Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med 16(1): 242, 2018. PMID: 30170620. DOI: 10.1186/s12967-018-1611-7
    OpenUrlCrossRefPubMed
  22. ↵
    1. Liu B,
    2. Li X,
    3. Li C,
    4. Xu R and
    5. Sun X
    : miR-25 mediates metastasis and epithelial-mesenchymal-transition in human esophageal squamous cell carcinoma via regulation of E-cadherin signaling. Bioengineered 10(1): 679-688, 2019. PMID: 31679450. DOI: 10.1080/21655979.2019.1687391
    OpenUrlCrossRefPubMed
  23. ↵
    1. Cavallaro U and
    2. Christofori G
    : Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2): 118-132, 2004. PMID: 14964308. DOI: 10.1038/nrc1276
    OpenUrlCrossRefPubMed
  24. ↵
    1. Bruner HC and
    2. Derksen PWB
    : Loss of E-cadherin-dependent cell-cell adhesion and the development and progression of cancer. Cold Spring Harb Perspect Biol 10(3): a029330, 2018. PMID: 28507022. DOI: 10.1101/cshperspect.a029330
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Li T,
    2. Xu L,
    3. Teng J,
    4. Ma Y,
    5. Liu W,
    6. Wang Y,
    7. Chi X,
    8. Shao S,
    9. Dong Y,
    10. Zhan Q and
    11. Liu X
    : GADD45G interacts with E-cadherin to suppress the migration and invasion of esophageal squamous cell carcinoma. Dig Dis Sci 65(4): 1032-1041, 2020. PMID: 31562612. DOI: 10.1007/s10620-019-05836-8
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ma J,
    2. Hong L,
    3. Xu G,
    4. Hao J,
    5. Wang R,
    6. Guo H,
    7. Liu J,
    8. Zhang Y,
    9. Nie Y and
    10. Fan D
    : miR-483-3p plays an oncogenic role in esophageal squamous cell carcinoma by targeting tumor suppressor EI24. Cell Biol Int 40(4): 448-455, 2016. PMID: 26801660. DOI: 10.1002/cbin.10585
    OpenUrlCrossRefPubMed
  27. ↵
    1. Gu Z,
    2. Flemington C,
    3. Chittenden T and
    4. Zambetti GP
    : ei24, a p53 response gene involved in growth suppression and apoptosis. Mol Cell Biol 20(1): 233-241, 2000. PMID: 10594026. DOI: 10.1128/MCB.20.1.233-241.2000
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Duan L,
    2. Ma J,
    3. Yang W,
    4. Cao L,
    5. Wang X,
    6. Niu L,
    7. Li Y,
    8. Zhou W,
    9. Zhang Y,
    10. Liu J,
    11. Zhang H,
    12. Zhao Q,
    13. Hong L and
    14. Fan D
    : EI24 inhibits cell proliferation and drug resistance of esophageal squamous cell carcinoma. Front Oncol 10: 1570, 2020. PMID: 32974192. DOI: 10.3389/fonc.2020.01570
    OpenUrlCrossRefPubMed
  29. ↵
    1. Choi JM,
    2. Devkota S,
    3. Sung YH and
    4. Lee HW
    : EI24 regulates epithelial-to-mesenchymal transition and tumor progression by suppressing TRAF2-mediated NF-κB activity. Oncotarget 4(12): 2383-2396, 2013. PMID: 24280371. DOI: 10.18632/oncotarget.1434
    OpenUrlCrossRefPubMed
  30. ↵
    1. Zhang W,
    2. Hong R,
    3. Li L,
    4. Wang Y,
    5. Du P,
    6. Ou Y,
    7. Zhao Z,
    8. Liu X,
    9. Xiao W,
    10. Dong D,
    11. Wu Q,
    12. Chen J,
    13. Song Y and
    14. Zhan Q
    : The chromosome 11q13.3 amplification associated lymph node metastasis is driven by miR-548k through modulating tumor microenvironment. Mol Cancer 17(1): 125, 2018. PMID: 30131072. DOI: 10.1186/s12943-018-0871-4
    OpenUrlCrossRefPubMed
  31. ↵
    1. Mullooly M,
    2. McGowan PM,
    3. Crown J and
    4. Duffy MJ
    : The ADAMs family of proteases as targets for the treatment of cancer. Cancer Biol Ther 17(8): 870-880, 2016. PMID: 27115328. DOI: 10.1080/15384047.2016.1177684
    OpenUrlCrossRefPubMed
    1. Inagaki J,
    2. Takahashi K,
    3. Ogawa H,
    4. Asano K,
    5. Faruk Hatipoglu O,
    6. Cilek MZ,
    7. Obika M,
    8. Ohtsuki T,
    9. Hofmann M,
    10. Kusachi S,
    11. Ninomiya Y and
    12. Hirohata S
    : ADAMTS1 inhibits lymphangiogenesis by attenuating phosphorylation of the lymphatic endothelial cell-specific VEGF receptor. Exp Cell Res 323(2): 263-275, 2014. PMID: 24631293. DOI: 10.1016/j.yexcr.2014.03.002
    OpenUrlCrossRefPubMed
    1. Zheng W,
    2. Aspelund A and
    3. Alitalo K
    : Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 124(3): 878-887, 2014. PMID: 24590272. DOI: 10.1172/JCI71603
    OpenUrlCrossRefPubMed
  32. ↵
    1. Vaahtomeri K,
    2. Karaman S,
    3. Mäkinen T and
    4. Alitalo K
    : Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev 31(16): 1615-1634, 2017. PMID: 28947496. DOI: 10.1101/gad.303776.117
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Memon A and
    2. Lee WK
    : KLF10 as a tumor suppressor gene and its TGF-β signaling. Cancers (Basel) 10(6): 161, 2018. PMID: 29799499. DOI: 10.3390/cancers10060161
    OpenUrlCrossRefPubMed
  34. ↵
    1. Kong R,
    2. Ma Y,
    3. Feng J,
    4. Li S,
    5. Zhang W,
    6. Jiang J,
    7. Zhang J,
    8. Qiao Z,
    9. Yang X and
    10. Zhou B
    : The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A. Cell Mol Biol Lett 21: 3, 2016. PMID: 28536606. DOI: 10.1186/s11658-016-0004-2
    OpenUrlCrossRefPubMed
  35. ↵
    1. Apte RS,
    2. Chen DS and
    3. Ferrara N
    : VEGF in signaling and disease: Beyond discovery and development. Cell 176(6): 1248-1264, 2019. PMID: 30849371. DOI: 10.1016/j.cell.2019.01.021
    OpenUrlCrossRefPubMed
  36. ↵
    1. Siveen KS,
    2. Prabhu K,
    3. Krishnankutty R,
    4. Kuttikrishnan S,
    5. Tsakou M,
    6. Alali FQ,
    7. Dermime S,
    8. Mohammad RM and
    9. Uddin S
    : Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: Potential and challenges. Curr Vasc Pharmacol 15(4): 339-351, 2017. PMID: 28056756. DOI: 10.2174/1570161115666170105124038
    OpenUrlCrossRefPubMed
  37. ↵
    1. Yang YM,
    2. Hong P,
    3. Xu WW,
    4. He QY and
    5. Li B
    : Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 5(1): 229, 2020. PMID: 33028804. DOI: 10.1038/s41392-020-00323-3
    OpenUrlCrossRefPubMed
  38. ↵
    1. Zhu JF,
    2. Liu Y,
    3. Huang H,
    4. Shan L,
    5. Han ZG,
    6. Liu JY,
    7. Li YL,
    8. Dong X and
    9. Zeng W
    : MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth. Cancer Cell Int 18: 193, 2018. PMID: 30479571. DOI: 10.1186/s12935-018-0684-y
    OpenUrlCrossRefPubMed
  39. ↵
    1. Ciardiello F and
    2. Tortora G
    : EGFR antagonists in cancer treatment. N Engl J Med 358(11): 1160-1174, 2008. PMID: 18337605. DOI: 10.1056/NEJMra0707704
    OpenUrlCrossRefPubMed
  40. ↵
    1. Guardiola S,
    2. Varese M,
    3. Sánchez-Navarro M and
    4. Giralt E
    : A third shot at EGFR: New opportunities in cancer therapy. Trends Pharmacol Sci 40(12): 941-955, 2019. PMID: 31706618. DOI: 10.1016/j.tips.2019.10.004
    OpenUrlCrossRefPubMed
  41. ↵
    1. Hong L,
    2. Han Y and
    3. Brain L
    : Epidermal growth factor receptor: an important target in esophageal cancer. Expert Opin Ther Targets 17(10): 1179-1185, 2013. PMID: 23855932. DOI: 10.1517/14728222.2013.820709
    OpenUrlCrossRefPubMed
  42. ↵
    1. Itakura Y,
    2. Sasano H,
    3. Shiga C,
    4. Furukawa Y,
    5. Shiga K,
    6. Mori S and
    7. Nagura H
    : Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74(3): 795-804, 1994. PMID: 8039107. DOI: 10.1002/1097-0142(19940801)74:3<795::aid-cncr2820740303>3.0.co;2-i
    OpenUrlCrossRefPubMed
  43. ↵
    1. Kitagawa Y,
    2. Ueda M,
    3. Ando N,
    4. Ozawa S,
    5. Shimizu N and
    6. Kitajima M
    : Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2(5): 909-914, 1996. PMID: 9816249.
    OpenUrlAbstract
  44. ↵
    1. Lin CH,
    2. Tsai CH,
    3. Yeh CT,
    4. Liang JL,
    5. Hung WC,
    6. Lin FC,
    7. Chang WL,
    8. Li HY,
    9. Yao YC,
    10. Hsu TI,
    11. Lee YC,
    12. Wang YC,
    13. Sheu BS,
    14. Lai WW,
    15. Calkins MJ,
    16. Hsiao M and
    17. Lu PJ
    : MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma. Oncotarget 7(26): 39680-39693, 2016. PMID: 27203740. DOI: 10.18632/oncotarget.9444
    OpenUrlCrossRefPubMed
  45. ↵
    1. Gros SJ,
    2. Kurschat N,
    3. Dohrmann T,
    4. Reichelt U,
    5. Dancau AM,
    6. Peldschus K,
    7. Adam G,
    8. Hoffman RM,
    9. Izbicki JR and
    10. Kaifi JT
    : Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 9(7): 2037-2045, 2010. PMID: 20606043. DOI: 10.1158/1535-7163.MCT-10-0209
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Kato H,
    2. Arao T,
    3. Matsumoto K,
    4. Fujita Y,
    5. Kimura H,
    6. Hayashi H,
    7. Nishiki K,
    8. Iwama M,
    9. Shiraishi O,
    10. Yasuda A,
    11. Shinkai M,
    12. Imano M,
    13. Imamoto H,
    14. Yasuda T,
    15. Okuno K,
    16. Shiozaki H and
    17. Nishio K
    : Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol 42(4): 1151-1158, 2013. PMID: 23426935. DOI: 10.3892/ijo.2013.1830
    OpenUrlCrossRefPubMed
    1. Gonzaga IM,
    2. Soares-Lima SC,
    3. de Santos PT,
    4. Blanco TC,
    5. de Reis BS,
    6. Quintella DC,
    7. de Oliveira IM,
    8. de Faria PA,
    9. Kruel CD,
    10. Andreollo NA,
    11. de Simão TA and
    12. Pinto LF
    : Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer 12: 569, 2012. PMID: 23207070. DOI: 10.1186/1471-2407-12-569
    OpenUrlCrossRefPubMed
    1. Schoppmann SF,
    2. Jesch B,
    3. Friedrich J,
    4. Wrba F,
    5. Schultheis A,
    6. Pluschnig U,
    7. Maresch J,
    8. Zacherl J,
    9. Hejna M and
    10. Birner P
    : Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 34(12): 1868-1873, 2010. PMID: 21107094. DOI: 10.1097/PAS.0b013e3181f8be17
    OpenUrlCrossRefPubMed
  47. ↵
    1. Fichter CD,
    2. Timme S,
    3. Braun JA,
    4. Gudernatsch V,
    5. Schöpflin A,
    6. Bogatyreva L,
    7. Geddert H,
    8. Faller G,
    9. Klimstra D,
    10. Tang L,
    11. Hauschke D,
    12. Werner M and
    13. Lassmann S
    : EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer 135(7): 1517-1530, 2014. PMID: 24510732. DOI: 10.1002/ijc.28771
    OpenUrlCrossRefPubMed
  48. ↵
    1. Kong KL,
    2. Kwong DL,
    3. Chan TH,
    4. Law SY,
    5. Chen L,
    6. Li Y,
    7. Qin YR and
    8. Guan XY
    : MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 61(1): 33-42, 2012. PMID: 21813472. DOI: 10.1136/gutjnl-2011-300178
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Zha J and
    2. Lackner MR
    : Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16(9): 2512-2517, 2010. PMID: 20388853. DOI: 10.1158/1078-0432.CCR-09-2232
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Ouban A,
    2. Muraca P,
    3. Yeatman T and
    4. Coppola D
    : Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34(8): 803-808, 2003. PMID: 14506643. DOI: 10.1016/s0046-8177(03)00291-0
    OpenUrlCrossRefPubMed
  51. ↵
    1. Liu YC,
    2. Leu CM,
    3. Wong FH,
    4. Fong WS,
    5. Chen SC,
    6. Chang C and
    7. Hu CP
    : Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 9(6 Pt 2): 665-674, 2002. PMID: 12432233. DOI: 10.1159/000067282
    OpenUrlCrossRefPubMed
  52. ↵
    1. Imsumran A,
    2. Adachi Y,
    3. Yamamoto H,
    4. Li R,
    5. Wang Y,
    6. Min Y,
    7. Piao W,
    8. Nosho K,
    9. Arimura Y,
    10. Shinomura Y,
    11. Hosokawa M,
    12. Lee CT,
    13. Carbone DP and
    14. Imai K
    : Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28(5): 947-956, 2007. PMID: 17183068. DOI: 10.1093/carcin/bgl247
    OpenUrlCrossRefPubMed
  53. ↵
    1. Doyle SL,
    2. Donohoe CL,
    3. Finn SP,
    4. Howard JM,
    5. Lithander FE,
    6. Reynolds JV,
    7. Pidgeon GP and
    8. Lysaght J
    : IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol 107(2): 196-204, 2012. PMID: 22146489. DOI: 10.1038/ajg.2011.417
    OpenUrlCrossRefPubMed
  54. ↵
    1. Zhang T,
    2. Shen H,
    3. Dong W,
    4. Qu X,
    5. Liu Q and
    6. Du J
    : Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma. Sci Rep 4: 6855, 2014. PMID: 25358597. DOI: 10.1038/srep06855
    OpenUrlCrossRefPubMed
  55. ↵
    1. Jing C,
    2. Ma G,
    3. Li X,
    4. Wu X,
    5. Huang F,
    6. Liu K and
    7. Liu Z
    : MicroRNA-17/20a impedes migration and invasion via TGF-β/ITGB6 pathway in esophageal squamous cell carcinoma. Am J Cancer Res 6(7): 1549-1562, 2016. PMID: 27508097.
    OpenUrlPubMed
  56. ↵
    1. Shi Y and
    2. Massagué J
    : Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6): 685-700, 2003. PMID: 12809600. DOI: 10.1016/s0092-8674(03)00432-x
    OpenUrlCrossRefPubMed
  57. ↵
    1. Chen YG
    : Endocytic regulation of TGF-beta signaling. Cell Res 19(1): 58-70, 2009. PMID: 19050695. DOI: 10.1038/cr.2008.315
    OpenUrlCrossRefPubMed
  58. ↵
    1. Massagué J
    : TGFbeta in cancer. Cell 134(2): 215-230, 2008. PMID: 18662538. DOI: 10.1016/j.cell.2008.07.001
    OpenUrlCrossRefPubMed
  59. ↵
    1. Massagué J
    : TGFβ signalling in context. Nat Rev Mol Cell Biol 13(10): 616-630, 2012. PMID: 22992590. DOI: 10.1038/nrm3434
    OpenUrlCrossRefPubMed
  60. ↵
    1. Ma G,
    2. Jing C,
    3. Li L,
    4. Huang F,
    5. Ding F,
    6. Wang B,
    7. Lin D,
    8. Luo A and
    9. Liu Z
    : MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell carcinoma. Oncotarget 7(15): 20209-20222, 2016. PMID: 26934001. DOI: 10.18632/oncotarget.7747
    OpenUrlCrossRefPubMed
  61. ↵
    1. Sulzmaier FJ,
    2. Jean C and
    3. Schlaepfer DD
    : FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14(9): 598-610, 2014. PMID: 25098269. DOI: 10.1038/nrc3792
    OpenUrlCrossRefPubMed
  62. ↵
    1. Hynes RO
    : Integrins: bidirectional, allosteric signaling machines. Cell 110(6): 673-687, 2002. PMID: 12297042. DOI: 10.1016/s0092-8674(02)00971-6
    OpenUrlCrossRefPubMed
  63. ↵
    1. Guo W and
    2. Giancotti FG
    : Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10): 816-826, 2004. PMID: 15459662. DOI: 10.1038/nrm1490
    OpenUrlCrossRefPubMed
  64. ↵
    1. Zuo J,
    2. Zhu K,
    3. Wang Y and
    4. Yu Z
    : MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. Mol Cell Biochem 443(1-2): 139-149, 2018. PMID: 29094237. DOI: 10.1007/s11010-017-3218-3
    OpenUrlCrossRefPubMed
  65. ↵
    1. Ponta H,
    2. Sherman L and
    3. Herrlich PA
    : CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1): 33-45, 2003. PMID: 12511867. DOI: 10.1038/nrm1004
    OpenUrlCrossRefPubMed
  66. ↵
    1. Chen C,
    2. Zhao S,
    3. Karnad A and
    4. Freeman JW
    : The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11(1): 64, 2018. PMID: 29747682. DOI: 10.1186/s13045-018-0605-5
    OpenUrlCrossRefPubMed
  67. ↵
    1. Goodison S,
    2. Urquidi V and
    3. Tarin D
    : CD44 cell adhesion molecules. Mol Pathol 52(4): 189-196, 1999. PMID: 10694938. DOI: 10.1136/mp.52.4.189
    OpenUrlAbstract
  68. ↵
    1. Weidle UH,
    2. Maisel D,
    3. Klostermann S,
    4. Weiss EH and
    5. Schmitt M
    : Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics Proteomics 8(5): 211-226, 2011. PMID: 21980036.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Le Bras GF,
    2. Allison GL,
    3. Richards NF,
    4. Ansari SS,
    5. Washington MK and
    6. Andl CD
    : CD44 upregulation in E-cadherin-negative esophageal cancers results in cell invasion. PLoS One 6(11): e27063, 2011. PMID: 22069487. DOI: 10.1371/journal.pone.0027063
    OpenUrlCrossRefPubMed
  70. ↵
    1. Zhao JS,
    2. Li WJ,
    3. Ge D,
    4. Zhang PJ,
    5. Li JJ,
    6. Lu CL,
    7. Ji XD,
    8. Guan DX,
    9. Gao H,
    10. Xu LY,
    11. Li EM,
    12. Soukiasian H,
    13. Koeffler HP,
    14. Wang XF and
    15. Xie D
    : Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 6(6): e21419, 2011. PMID: 21731740. DOI: 10.1371/journal.pone.0021419
    OpenUrlCrossRefPubMed
  71. ↵
    1. Kamil Mohammed Al-Mosawi A,
    2. Cheshomi H,
    3. Hosseinzadeh A and
    4. M Matin M
    : Prognostic and clinical value of CD44 and CD133 in esophageal cancer: a systematic review and meta-analysis. Iran J Allergy Asthma Immunol 19(2): 105-116, 2020. PMID: 32372624. DOI: 10.18502/ijaai.v19i2.2756
    OpenUrlCrossRefPubMed
  72. ↵
    1. Suzuki S,
    2. Yokobori T,
    3. Tanaka N,
    4. Sakai M,
    5. Sano A,
    6. Inose T,
    7. Sohda M,
    8. Nakajima M,
    9. Miyazaki T,
    10. Kato H and
    11. Kuwano H
    : CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 28(2): 465-472, 2012. PMID: 22641236. DOI: 10.3892/or.2012.1831
    OpenUrlCrossRefPubMed
  73. ↵
    1. Feng M,
    2. Jiang W,
    3. Kim BYS,
    4. Zhang CC,
    5. Fu YX and
    6. Weissman IL
    : Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer 19(10): 568-586, 2019. PMID: 31462760. DOI: 10.1038/s41568-019-0183-z
    OpenUrlCrossRefPubMed
    1. Chao MP,
    2. Takimoto CH,
    3. Feng DD,
    4. McKenna K,
    5. Gip P,
    6. Liu J,
    7. Volkmer JP,
    8. Weissman IL and
    9. Majeti R
    : Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol 9: 1380, 2020. PMID: 32038992. DOI: 10.3389/fonc.2019.01380
    OpenUrlCrossRefPubMed
  74. ↵
    1. Murata Y,
    2. Saito Y,
    3. Kotani T and
    4. Matozaki T
    : CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci 109(8): 2349-2357, 2018. PMID: 29873856. DOI: 10.1111/cas.13663
    OpenUrlCrossRefPubMed
  75. ↵
    1. Zhao CL,
    2. Yu S,
    3. Wang SH,
    4. Li SG,
    5. Wang ZJ and
    6. Han SN
    : Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer. Oncol Lett 15(2): 2017-2023, 2018. PMID: 29399202. DOI: 10.3892/ol.2017.7447
    OpenUrlCrossRefPubMed
  76. ↵
    1. Li B,
    2. Xu WW,
    3. Han L,
    4. Chan KT,
    5. Tsao SW,
    6. Lee NPY,
    7. Law S,
    8. Xu LY,
    9. Li EM,
    10. Chan KW,
    11. Qin YR,
    12. Guan XY,
    13. He QY and
    14. Cheung ALM
    : MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene 36(28): 3986-4000, 2017. PMID: 28288140. DOI: 10.1038/onc.2017.29
    OpenUrlCrossRefPubMed
  77. ↵
    1. Glumac PM and
    2. LeBeau AM
    : The role of CD133 in cancer: a concise review. Clin Transl Med 7(1): 18, 2018. PMID: 29984391. DOI: 10.1186/s40169-018-0198-1
    OpenUrlCrossRefPubMed
  78. ↵
    1. Valent P,
    2. Bonnet D,
    3. De Maria R,
    4. Lapidot T,
    5. Copland M,
    6. Melo JV,
    7. Chomienne C,
    8. Ishikawa F,
    9. Schuringa JJ,
    10. Stassi G,
    11. Huntly B,
    12. Herrmann H,
    13. Soulier J,
    14. Roesch A,
    15. Schuurhuis GJ,
    16. Wöhrer S,
    17. Arock M,
    18. Zuber J,
    19. Cerny-Reiterer S,
    20. Johnsen HE,
    21. Andreeff M and
    22. Eaves C
    : Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12(11): 767-775, 2012. PMID: 23051844. DOI: 10.1038/nrc3368
    OpenUrlCrossRefPubMed
  79. ↵
    1. Liou GY
    : CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol 106: 1-7, 2019. PMID: 30399449. DOI: 10.1016/j.biocel.2018.10.013
    OpenUrlCrossRefPubMed
  80. ↵
    1. Xu WW,
    2. Li B,
    3. Zhao JF,
    4. Yang JG,
    5. Li JQ,
    6. Tsao SW,
    7. He QY and
    8. Cheung ALM
    : IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness. Cancer Lett 425: 88-100, 2018. PMID: 29604392. DOI: 10.1016/j.canlet.2018.03.039
    OpenUrlCrossRefPubMed
  81. ↵
    1. Sui YP,
    2. Jian XP,
    3. Ma LI,
    4. Xu GZ,
    5. Liao HW,
    6. Liu YP and
    7. Wen HC
    : Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis. Mol Clin Oncol 4(1): 77-82, 2016. PMID: 26870362. DOI: 10.3892/mco.2015.651
    OpenUrlCrossRefPubMed
  82. ↵
    1. Jing R,
    2. Chen W,
    3. Wang H,
    4. Ju S,
    5. Cong H,
    6. Sun B,
    7. Jin Q,
    8. Chu S,
    9. Xu L and
    10. Cui M
    : Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE. Am J Physiol Gastrointest Liver Physiol 309(9): G719-G729, 2015. PMID: 26316588. DOI: 10.1152/ajpgi.00078.2015
    OpenUrlCrossRefPubMed
  83. ↵
    1. Palanissami G and
    2. Paul SFD
    : RAGE and its ligands: Molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Horm Cancer 9(5): 295-325, 2018. PMID: 29987748. DOI: 10.1007/s12672-018-0342-9
    OpenUrlCrossRefPubMed
  84. ↵
    1. Jangde N,
    2. Ray R and
    3. Rai V
    : RAGE and its ligands: from pathogenesis to therapeutics. Crit Rev Biochem Mol Biol 55(6): 555-575, 2020. PMID: 32933340. DOI: 10.1080/10409238.2020.1819194
    OpenUrlCrossRefPubMed
  85. ↵
    1. Tateno T,
    2. Ueno S,
    3. Hiwatashi K,
    4. Matsumoto M,
    5. Okumura H,
    6. Setoyama T,
    7. Uchikado Y,
    8. Sakoda M,
    9. Kubo F,
    10. Ishigami S,
    11. Shinchi H and
    12. Natsugoe S
    : Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 16(2): 440-446, 2009. PMID: 19023628. DOI: 10.1245/s10434-008-0237-z
    OpenUrlCrossRefPubMed
  86. ↵
    1. Shi W,
    2. Song J,
    3. Gao Z,
    4. Liu X and
    5. Wang W
    : Downregulation of miR-7-5p inhibits the tumorigenesis of esophagus cancer via targeting KLF4. Onco Targets Ther 13: 9443-9453, 2020. PMID: 33061430. DOI: 10.2147/OTT.S251508
    OpenUrlCrossRefPubMed
  87. ↵
    1. Ghaleb AM and
    2. Yang VW
    : Krüppel-like factor 4 (KLF4): What we currently know. Gene 611: 27-37, 2017. PMID: 28237823. DOI: 10.1016/j.gene.2017.02.025
    OpenUrlCrossRefPubMed
  88. ↵
    1. Taracha-Wisniewska A,
    2. Kotarba G,
    3. Dworkin S and
    4. Wilanowski T
    : Recent discoveries on the involvement of Krüppel-like factor 4 in the most common cancer types. Int J Mol Sci 21(22): 8843, 2020. PMID: 33266506. DOI: 10.3390/ijms21228843
    OpenUrlCrossRefPubMed
  89. ↵
    1. He H,
    2. Li S,
    3. Hong Y,
    4. Zou H,
    5. Chen H,
    6. Ding F,
    7. Wan Y and
    8. Liu Z
    : Krüppel-like factor 4 promotes esophageal squamous cell carcinoma differentiation by up-regulating Keratin 13 expression. J Biol Chem 290(21): 13567-13577, 2015. PMID: 25851906. DOI: 10.1074/jbc.M114.629717
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Ma MQ,
    2. Zhang HD,
    3. Tang P,
    4. Jiang HJ and
    5. Chen CG
    : Association of Kruppel-like factor 4 expression with the prognosis of esophageal squamous cell carcinoma patients. Int J Clin Exp Pathol 7(10): 6679-6685, 2014. PMID: 25400747.
    OpenUrlPubMed
  91. ↵
    1. Wu K,
    2. Hu Y,
    3. Yan K,
    4. Qi Y,
    5. Zhang C,
    6. Zhu D,
    7. Liu D and
    8. Zhao S
    : microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer. J Cell Physiol 235(2): 1247-1258, 2020. PMID: 31267531. DOI: 10.1002/jcp.29040
    OpenUrlCrossRefPubMed
  92. ↵
    1. Mirza AZ,
    2. Althagafi II and
    3. Shamshad H
    : Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem 166: 502-513, 2019. PMID: 30739829. DOI: 10.1016/j.ejmech.2019.01.067
    OpenUrlCrossRefPubMed
  93. ↵
    1. Yousefnia S,
    2. Momenzadeh S,
    3. Seyed Forootan F,
    4. Ghaedi K and
    5. Nasr Esfahani MH
    : The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity. Gene 649: 14-22, 2018. PMID: 29369787. DOI: 10.1016/j.gene.2018.01.018
    OpenUrlCrossRefPubMed
  94. ↵
    1. Wu K,
    2. Yang Y,
    3. Liu D,
    4. Qi Y,
    5. Zhang C,
    6. Zhao J and
    7. Zhao S
    : Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget 7(28): 44572-44582, 2016. PMID: 27323819. DOI: 10.18632/oncotarget.10067
    OpenUrlCrossRefPubMed
  95. ↵
    1. Terashita Y,
    2. Sasaki H,
    3. Haruki N,
    4. Nishiwaki T,
    5. Ishiguro H,
    6. Shibata Y,
    7. Kudo J,
    8. Konishi S,
    9. Kato J,
    10. Koyama H,
    11. Kimura M,
    12. Sato A,
    13. Shinoda N,
    14. Kuwabara Y and
    15. Fujii Y
    : Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32(7): 238-243, 2002. PMID: 12324573. DOI: 10.1093/jjco/hyf056
    OpenUrlCrossRefPubMed
  96. ↵
    1. Liu YT,
    2. Zong D,
    3. Jiang XS,
    4. Yin L,
    5. Wang LJ,
    6. Wang TT,
    7. Zhu J and
    8. He X
    : miR-32 promotes esophageal squamous cell carcinoma metastasis by targeting CXXC5. J Cell Biochem 120(4): 6250-6263, 2019. PMID: 30362164. DOI: 10.1002/jcb.27912
    OpenUrlCrossRefPubMed
  97. ↵
    1. Xiong X,
    2. Tu S,
    3. Wang J,
    4. Luo S and
    5. Yan X
    : CXXC5: A novel regulator and coordinator of TGF-β, BMP and Wnt signaling. J Cell Mol Med 23(2): 740-749, 2019. PMID: 30479059. DOI: 10.1111/jcmm.14046
    OpenUrlCrossRefPubMed
    1. Andersson T,
    2. Södersten E,
    3. Duckworth JK,
    4. Cascante A,
    5. Fritz N,
    6. Sacchetti P,
    7. Cervenka I,
    8. Bryja V and
    9. Hermanson O
    : CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem 284(6): 3672-3681, 2009. PMID: 19001364. DOI: 10.1074/jbc.M808119200
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Zhang M,
    2. Wang R,
    3. Wang Y,
    4. Diao F,
    5. Lu F,
    6. Gao D,
    7. Chen D,
    8. Zhai Z and
    9. Shu H
    : The CXXC finger 5 protein is required for DNA damage-induced p53 activation. Sci China C Life Sci 52(6): 528-538, 2009. PMID: 19557330. DOI: 10.1007/s11427-009-0083-7
    OpenUrlCrossRefPubMed
  99. ↵
    1. Yan X,
    2. Wu J,
    3. Jiang Q,
    4. Cheng H,
    5. Han JJ and
    6. Chen YG
    : CXXC5 suppresses hepatocellular carcinoma by promoting TGF-β-induced cell cycle arrest and apoptosis. J Mol Cell Biol 10(1): 48-59, 2018. PMID: 29036306. DOI: 10.1093/jmcb/mjx042
    OpenUrlCrossRefPubMed
  100. ↵
    1. Ma J,
    2. Zhan Y,
    3. Xu Z,
    4. Li Y,
    5. Luo A,
    6. Ding F,
    7. Cao X,
    8. Chen H and
    9. Liu Z
    : ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. Cancer Lett 398: 37-45, 2017. PMID: 28408353. DOI: 10.1016/j.canlet.2017.04.006
    OpenUrlCrossRefPubMed
  101. ↵
    1. Kurkewich JL,
    2. Klopfenstein N,
    3. Hallas WM,
    4. Wood C,
    5. Sattler RA,
    6. Das C,
    7. Tucker H,
    8. Dahl R and
    9. Cowden Dahl KD
    : Arid3b is critical for B lymphocyte development. PLoS One 11(8): e0161468, 2016. PMID: 27537840. DOI: 10.1371/journal.pone.0161468
    OpenUrlCrossRefPubMed
  102. ↵
    1. Samyesudhas SJ,
    2. Roy L and
    3. Cowden Dahl KD
    : Differential expression of ARID3B in normal adult tissue and carcinomas. Gene 543(1): 174-180, 2014. PMID: 24704276. DOI: 10.1016/j.gene.2014.04.007
    OpenUrlCrossRefPubMed
  103. ↵
    1. Zhang Y,
    2. Xu Y,
    3. Li Z,
    4. Zhu Y,
    5. Wen S,
    6. Wang M,
    7. Lv H,
    8. Zhang F and
    9. Tian Z
    : Identification of the key transcription factors in esophageal squamous cell carcinoma. J Thorac Dis 10(1): 148-161, 2018. PMID: 29600044. DOI: 10.21037/jtd.2017.12.27
    OpenUrlCrossRefPubMed
  104. ↵
    1. Liu M,
    2. Yu J,
    3. Wang D,
    4. Niu Y,
    5. Chen S,
    6. Gao P,
    7. Yang Z,
    8. Wang H,
    9. Zhang J,
    10. Zhang C,
    11. Zhao Y,
    12. Hu W and
    13. Sun G
    : Epigenetically upregulated MicroRNA-602 is involved in a negative feedback loop with FOXK2 in esophageal squamous cell carcinoma. Mol Ther 27(10): 1796-1809, 2019. PMID: 31401147. DOI: 10.1016/j.ymthe.2019.07.006
    OpenUrlCrossRefPubMed
  105. ↵
    1. Nestal de Moraes G,
    2. Carneiro LDT,
    3. Maia RC,
    4. Lam EW and
    5. Sharrocks AD
    : FOXK2 transcription factor and its emerging roles in cancer. Cancers (Basel) 11(3): 393, 2019. PMID: 30897782. DOI: 10.3390/cancers11030393
    OpenUrlCrossRefPubMed
  106. ↵
    1. Liu Y,
    2. Ding W,
    3. Ge H,
    4. Ponnusamy M,
    5. Wang Q,
    6. Hao X,
    7. Wu W,
    8. Zhang Y,
    9. Yu W,
    10. Ao X and
    11. Wang J
    : FOXK transcription factors: Regulation and critical role in cancer. Cancer Lett 458: 1-12, 2019. PMID: 31132431. DOI: 10.1016/j.canlet.2019.05.030
    OpenUrlCrossRefPubMed
  107. ↵
    1. Liu X,
    2. Wei X,
    3. Niu W,
    4. Wang D,
    5. Wang B and
    6. Zhuang H
    : Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer. Mol Med Rep 18(5): 4356-4364, 2018. PMID: 30221666. DOI: 10.3892/mmr.2018.9466
    OpenUrlCrossRefPubMed
  108. ↵
    1. Cheng Y,
    2. Li Y,
    3. Nian Y,
    4. Liu D,
    5. Dai F and
    6. Zhang J
    : STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells. BMC Cancer 15: 306, 2015. PMID: 25928665. DOI: 10.1186/s12885-015-1303-0
    OpenUrlCrossRefPubMed
  109. ↵
    1. Furtek SL,
    2. Backos DS,
    3. Matheson CJ and
    4. Reigan P
    : Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol 11(2): 308-318, 2016. PMID: 26730496. DOI: 10.1021/acschembio.5b00945
    OpenUrlCrossRefPubMed
  110. ↵
    1. Yu H,
    2. Lee H,
    3. Herrmann A,
    4. Buettner R and
    5. Jove R
    : Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14(11): 736-746, 2014. PMID: 25342631. DOI: 10.1038/nrc3818
    OpenUrlCrossRefPubMed
  111. ↵
    1. Lee H,
    2. Jeong AJ and
    3. Ye SK
    : Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep 52(7): 415-423, 2019. PMID: 31186087.
    OpenUrlPubMed
  112. ↵
    1. Hemmann U,
    2. Gerhartz C,
    3. Heesel B,
    4. Sasse J,
    5. Kurapkat G,
    6. Grötzinger J,
    7. Wollmer A,
    8. Zhong Z,
    9. Darnell JE Jr.,
    10. Graeve L,
    11. Heinrich PC and
    12. Horn F
    : Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem 271(22): 12999-13007, 1996. PMID: 8662795. DOI: 10.1074/jbc.271.22.12999
    OpenUrlAbstract/FREE Full Text
  113. ↵
    1. Wang Z,
    2. Zhu S,
    3. Shen M,
    4. Liu J,
    5. Wang M,
    6. Li C,
    7. Wang Y,
    8. Deng A and
    9. Mei Q
    : STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis 34(3): 678-688, 2013. PMID: 23172665. DOI: 10.1093/carcin/bgs361
    OpenUrlCrossRefPubMed
  114. ↵
    1. Timme S,
    2. Ihde S,
    3. Fichter CD,
    4. Waehle V,
    5. Bogatyreva L,
    6. Atanasov K,
    7. Kohler I,
    8. Schöpflin A,
    9. Geddert H,
    10. Faller G,
    11. Klimstra D,
    12. Tang L,
    13. Reinheckel T,
    14. Hauschke D,
    15. Busch H,
    16. Boerries M,
    17. Werner M and
    18. Lassmann S
    : STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett’s adenocarcinomas. Oncogene 33(25): 3256-3266, 2014. PMID: 23912451. DOI: 10.1038/onc.2013.298
    OpenUrlCrossRefPubMed
  115. ↵
    1. Tian X,
    2. Fei Q,
    3. Du M,
    4. Zhu H,
    5. Ye J,
    6. Qian L,
    7. Lu Z,
    8. Zhang W,
    9. Wang Y,
    10. Peng F,
    11. Chen J,
    12. Liu B,
    13. Li Q,
    14. He X and
    15. Yin L
    : miR-130a-3p regulated TGF-β1-induced epithelial-mesenchymal transition depends on SMAD4 in EC-1 cells. Cancer Med 8(3): 1197-1208, 2019. PMID: 30741461. DOI: 10.1002/cam4.1981
    OpenUrlCrossRefPubMed
  116. ↵
    1. Zhao M,
    2. Mishra L and
    3. Deng CX
    : The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci 14(2): 111-123, 2018. PMID: 29483830. DOI: 10.7150/ijbs.23230
    OpenUrlCrossRefPubMed
  117. ↵
    1. Deckers M,
    2. van Dinther M,
    3. Buijs J,
    4. Que I,
    5. Löwik C,
    6. van der Pluijm G and
    7. ten Dijke P
    : The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66(4): 2202-2209, 2006. PMID: 16489022. DOI: 10.1158/0008-5472.CAN-05-3560
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Colak S and
    2. Ten Dijke P
    : Targeting TGF-β signaling in cancer. Trends Cancer 3(1): 56-71, 2017. PMID: 28718426. DOI: 10.1016/j.trecan.2016.11.008
    OpenUrlCrossRefPubMed
  119. ↵
    1. Syed V
    : TGF-β signaling in cancer. J Cell Biochem 117(6): 1279-1287, 2016. PMID: 26774024. DOI: 10.1002/jcb.25496
    OpenUrlCrossRefPubMed
  120. ↵
    1. Li S,
    2. Qin X,
    3. Li Y,
    4. Zhang X,
    5. Niu R,
    6. Zhang H,
    7. Cui A,
    8. An W and
    9. Wang X
    : MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4. Am J Transl Res 7(8): 1390-1403, 2015. PMID: 26396670.
    OpenUrlPubMed
  121. ↵
    1. Penzo-Méndez AI
    : Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 42(3): 425-428, 2010. PMID: 19651233. DOI: 10.1016/j.biocel.2009.07.018
    OpenUrlCrossRefPubMed
  122. ↵
    1. Lee AK,
    2. Ahn SG,
    3. Yoon JH and
    4. Kim SA
    : Sox4 stimulates ß-catenin activity through induction of CK2. Oncol Rep 25(2): 559-565, 2011. PMID: 21165564. DOI: 10.3892/or.2010.1091
    OpenUrlCrossRefPubMed
  123. ↵
    1. Tiwari N,
    2. Tiwari VK,
    3. Waldmeier L,
    4. Balwierz PJ,
    5. Arnold P,
    6. Pachkov M,
    7. Meyer-Schaller N,
    8. Schübeler D,
    9. van Nimwegen E and
    10. Christofori G
    : Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23(6): 768-783, 2013. PMID: 23764001. DOI: 10.1016/j.ccr.2013.04.020
    OpenUrlCrossRefPubMed
  124. ↵
    1. Vervoort SJ,
    2. Lourenço AR,
    3. van Boxtel R and
    4. Coffer PJ
    : SOX4 mediates TGF-β-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One 8(1): e53238, 2013. PMID: 23301048. DOI: 10.1371/journal.pone.0053238
    OpenUrlCrossRefPubMed
  125. ↵
    1. Wang F,
    2. Xia J,
    3. Wang N and
    4. Zong H
    : miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. Onkologie 36(12): 754-758, 2013. PMID: 24356567. DOI: 10.1159/000356978
    OpenUrlCrossRefPubMed
  126. ↵
    1. Schuhmacher M,
    2. Kohlhuber F,
    3. Hölzel M,
    4. Kaiser C,
    5. Burtscher H,
    6. Jarsch M,
    7. Bornkamm GW,
    8. Laux G,
    9. Polack A,
    10. Weidle UH and
    11. Eick D
    : The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 29(2): 397-406, 2001. PMID: 11139609. DOI: 10.1093/nar/29.2.397
    OpenUrlCrossRefPubMed
    1. Schuhmacher M,
    2. Staege MS,
    3. Pajic A,
    4. Polack A,
    5. Weidle UH,
    6. Bornkamm GW,
    7. Eick D and
    8. Kohlhuber F
    : Control of cell growth by c-Myc in the absence of cell division. Curr Biol 9(21): 1255-1258, 1999. PMID: 10556095. DOI: 10.1016/s0960-9822(99)80507-7
    OpenUrlCrossRefPubMed
  127. ↵
    1. Schlosser I,
    2. Hölzel M,
    3. Mürnseer M,
    4. Burtscher H,
    5. Weidle UH and
    6. Eick D
    : A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res 31(21): 6148-6156, 2003. PMID: 14576301. DOI: 10.1093/nar/gkg794
    OpenUrlCrossRefPubMed
  128. ↵
    1. Wang J,
    2. Liu Z,
    3. Wang Z,
    4. Wang S,
    5. Chen Z,
    6. Li Z,
    7. Zhang M,
    8. Zou J,
    9. Dong B,
    10. Gao J and
    11. Shen L
    : Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Lett 419: 64-74, 2018. PMID: 29366803. DOI: 10.1016/j.canlet.2018.01.051
    OpenUrlCrossRefPubMed
  129. ↵
    1. Lian Y,
    2. Niu X,
    3. Cai H,
    4. Yang X,
    5. Ma H,
    6. Ma S,
    7. Zhang Y and
    8. Chen Y
    : Clinicopathological significance of c-MYC in esophageal squamous cell carcinoma. Tumour Biol 39(7): 1010428317715804, 2017. PMID: 28671049. DOI: 10.1177/1010428317715804
    OpenUrlCrossRefPubMed
  130. ↵
    1. Villanueva MT
    : Long path to MYC inhibition approaches clinical trials. Nat Rev Cancer 19(5): 252, 2019. PMID: 30967650. DOI: 10.1038/s41568-019-0141-9
    OpenUrlCrossRefPubMed
  131. ↵
    1. Yokobori T,
    2. Suzuki S,
    3. Tanaka N,
    4. Inose T,
    5. Sohda M,
    6. Sano A,
    7. Sakai M,
    8. Nakajima M,
    9. Miyazaki T,
    10. Kato H and
    11. Kuwano H
    : MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 104(1): 48-54, 2013. PMID: 23013135. DOI: 10.1111/cas.12030
    OpenUrlCrossRefPubMed
  132. ↵
    1. Zhang P,
    2. Sun Y and
    3. Ma L
    : ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14(4): 481-487, 2015. PMID: 25607528. DOI: 10.1080/15384101.2015.1006048
    OpenUrlCrossRefPubMed
  133. ↵
    1. Caramel J,
    2. Ligier M and
    3. Puisieux A
    : Pleiotropic roles for ZEB1 in cancer. Cancer Res 78(1): 30-35, 2018. PMID: 29254997. DOI: 10.1158/0008-5472.CAN-17-2476
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Yang X,
    2. Wang Q,
    3. Dai W,
    4. Zhang J and
    5. Chen X
    : Overexpression of zinc finger E-box binding homeobox factor 1 promotes tumor invasiveness and confers unfavorable prognosis in esophageal squamous cell carcinoma. Tumour Biol 35(12): 11977-11984, 2014. PMID: 25142232. DOI: 10.1007/s13277-014-2494-8
    OpenUrlCrossRefPubMed
  135. ↵
    1. Sun Y,
    2. Yu X and
    3. Bai Q
    : miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. Int J Clin Exp Pathol 8(10): 12775-12783, 2015. PMID: 26722467.
    OpenUrlPubMed
  136. ↵
    1. Calissi G,
    2. Lam EW and
    3. Link W
    : Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov 20(1): 21-38, 2021. PMID: 33173189. DOI: 10.1038/s41573-020-0088-2
    OpenUrlCrossRefPubMed
  137. ↵
    1. Gartel AL
    : FOXM1 in cancer: Interactions and vulnerabilities. Cancer Res 77(12): 3135-3139, 2017. PMID: 28584182. DOI: 10.1158/0008-5472.CAN-16-3566
    OpenUrlAbstract/FREE Full Text
  138. ↵
    1. Liao GB,
    2. Li XZ,
    3. Zeng S,
    4. Liu C,
    5. Yang SM,
    6. Yang L,
    7. Hu CJ and
    8. Bai JY
    : Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal 16(1): 57, 2018. PMID: 30208972. DOI: 10.1186/s12964-018-0266-6
    OpenUrlCrossRefPubMed
  139. ↵
    1. Song L,
    2. Wang X and
    3. Feng Z
    : Overexpression of FOXM1 as a target for malignant progression of esophageal squamous cell carcinoma. Oncol Lett 15(4): 5910-5914, 2018. PMID: 29552222. DOI: 10.3892/ol.2018.8035
    OpenUrlCrossRefPubMed
  140. ↵
    1. Yamamoto S,
    2. Inoue J,
    3. Kawano T,
    4. Kozaki K,
    5. Omura K and
    6. Inazawa J
    : The impact of miRNA-based molecular diagnostics and treatment of NRF2-stabilized tumors. Mol Cancer Res 12(1): 58-68, 2014. PMID: 24307696. DOI: 10.1158/1541-7786.MCR-13-0246-T
    OpenUrlAbstract/FREE Full Text
  141. ↵
    1. Jaramillo MC and
    2. Zhang DD
    : The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27(20): 2179-2191, 2013. PMID: 24142871. DOI: 10.1101/gad.225680.113
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Rojo de la Vega M,
    2. Chapman E and
    3. Zhang DD
    : NRF2 and the hallmarks of cancer. Cancer Cell 34(1): 21-43, 2018. PMID: 29731393. DOI: 10.1016/j.ccell.2018.03.022
    OpenUrlCrossRefPubMed
    1. Menegon S,
    2. Columbano A and
    3. Giordano S
    : The dual roles of NRF2 in cancer. Trends Mol Med 22(7): 578-593, 2016. PMID: 27263465. DOI: 10.1016/j.molmed.2016.05.002
    OpenUrlCrossRefPubMed
  143. ↵
    1. Kitamura H and
    2. Motohashi H
    : NRF2 addiction in cancer cells. Cancer Sci 109(4): 900-911, 2018. PMID: 29450944. DOI: 10.1111/cas.13537
    OpenUrlCrossRefPubMed
  144. ↵
    1. Kitano Y,
    2. Baba Y,
    3. Nakagawa S,
    4. Miyake K,
    5. Iwatsuki M,
    6. Ishimoto T,
    7. Yamashita YI,
    8. Yoshida N,
    9. Watanabe M,
    10. Nakao M and
    11. Baba H
    : Nrf2 promotes oesophageal cancer cell proliferation via metabolic reprogramming and detoxification of reactive oxygen species. J Pathol 244(3): 346-357, 2018. PMID: 29243822. DOI: 10.1002/path.5021
    OpenUrlCrossRefPubMed
  145. ↵
    1. Xia D,
    2. Zhang XR,
    3. Ma YL,
    4. Zhao ZJ,
    5. Zhao R and
    6. Wang YY
    : Nrf2 promotes esophageal squamous cell carcinoma (ESCC) resistance to radiotherapy through the CaMKIIα-associated activation of autophagy. Cell Biosci 10: 90, 2020. PMID: 32760495. DOI: 10.1186/s13578-020-00456-6
    OpenUrlCrossRefPubMed
  146. ↵
    1. Shibata T,
    2. Kokubu A,
    3. Saito S,
    4. Narisawa-Saito M,
    5. Sasaki H,
    6. Aoyagi K,
    7. Yoshimatsu Y,
    8. Tachimori Y,
    9. Kushima R,
    10. Kiyono T and
    11. Yamamoto M
    : NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13(9): 864-873, 2011. PMID: 21969819. DOI: 10.1593/neo.11750
    OpenUrlCrossRefPubMed
  147. ↵
    1. Jin L,
    2. Yi J,
    3. Gao Y,
    4. Han S,
    5. He Z,
    6. Chen L and
    7. Song H
    : MiR-630 inhibits invasion and metastasis in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 48(9): 810-819, 2016. PMID: 27563011. DOI: 10.1093/abbs/gmw073
    OpenUrlCrossRefPubMed
  148. ↵
    1. Hasan MR,
    2. Sharma R,
    3. Saraya A,
    4. Chattopadhyay TK,
    5. DattaGupta S,
    6. Walfish PG,
    7. Chauhan SS and
    8. Ralhan R
    : Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients. PLoS One 8(12): e82846, 2013. PMID: 24367561. DOI: 10.1371/journal.pone.0082846
    OpenUrlCrossRefPubMed
  149. ↵
    1. Alves CC,
    2. Carneiro F,
    3. Hoefler H and
    4. Becker KF
    : Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci (Landmark Ed) 14: 3035-3050, 2009. PMID: 19273255. DOI: 10.2741/3433
    OpenUrlCrossRefPubMed
  150. ↵
    1. Zhou W,
    2. Gross KM and
    3. Kuperwasser C
    : Molecular regulation of Snai2 in development and disease. J Cell Sci 132(23): jcs235127, 2019. PMID: 31792043. DOI: 10.1242/jcs.235127
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Tang P,
    2. Yu Z,
    3. Zhang K,
    4. Wang Y,
    5. Ma Z,
    6. Zhang S,
    7. Chen D and
    8. Zhou Y
    : Slug down-regulation by RNA interference inhibits invasion growth in human esophageal squamous cell carcinoma. BMC Gastroenterol 11: 60, 2011. PMID: 21599940. DOI: 10.1186/1471-230X-11-60
    OpenUrlCrossRefPubMed
  152. ↵
    1. Zhang JX,
    2. Chen ZH,
    3. Xu Y,
    4. Chen JW,
    5. Weng HW,
    6. Yun M,
    7. Zheng ZS,
    8. Chen C,
    9. Wu BL,
    10. Li EM,
    11. Fu JH,
    12. Ye S and
    13. Xie D
    : Downregulation of MicroRNA-644a promotes esophageal squamous cell carcinoma aggressiveness and stem cell-like phenotype via dysregulation of PITX2. Clin Cancer Res 23(1): 298-310, 2017. PMID: 27407092. DOI: 10.1158/1078-0432.CCR-16-0414
    OpenUrlAbstract/FREE Full Text
  153. ↵
    1. Logan M,
    2. Pagán-Westphal SM,
    3. Smith DM,
    4. Paganessi L and
    5. Tabin CJ
    : The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals. Cell 94(3): 307-317, 1998. PMID: 9708733. DOI: 10.1016/s0092-8674(00)81474-9
    OpenUrlCrossRefPubMed
  154. ↵
    1. Buckingham M and
    2. Rigby PW
    : Gene regulatory networks and transcriptional mechanisms that control myogenesis. Dev Cell 28(3): 225-238, 2014. PMID: 24525185. DOI: 10.1016/j.devcel.2013.12.020
    OpenUrlCrossRefPubMed
  155. ↵
    1. Zhang JX,
    2. Tong ZT,
    3. Yang L,
    4. Wang F,
    5. Chai HP,
    6. Zhang F,
    7. Xie MR,
    8. Zhang AL,
    9. Wu LM,
    10. Hong H,
    11. Yin L,
    12. Wang H,
    13. Wang HY and
    14. Zhao Y
    : PITX2: a promising predictive biomarker of patients’ prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer 132(11): 2567-2577, 2013. PMID: 23132660. DOI: 10.1002/ijc.27930
    OpenUrlCrossRefPubMed
  156. ↵
    1. Mu Y,
    2. Wang Q,
    3. Tan L,
    4. Lin L and
    5. Zhang B
    : microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma. Oncol Lett 19(4): 3079-3088, 2020. PMID: 32256808. DOI: 10.3892/ol.2020.11420
    OpenUrlCrossRefPubMed
  157. ↵
    1. Bensaad K,
    2. Tsuruta A,
    3. Selak MA,
    4. Vidal MN,
    5. Nakano K,
    6. Bartrons R,
    7. Gottlieb E and
    8. Vousden KH
    : TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126(1): 107-120, 2006. PMID: 16839880. DOI: 10.1016/j.cell.2006.05.036
    OpenUrlCrossRefPubMed
  158. ↵
    1. Geng J,
    2. Yuan X,
    3. Wei M,
    4. Wu J and
    5. Qin ZH
    : The diverse role of TIGAR in cellular homeostasis and cancer. Free Radic Res 52(11-12): 1240-1249, 2018. PMID: 30284488. DOI: 10.1080/10715762.2018.1489133
    OpenUrlCrossRefPubMed
  159. ↵
    1. Chu J,
    2. Niu X,
    3. Chang J,
    4. Shao M,
    5. Peng L,
    6. Xi Y,
    7. Lin A,
    8. Wang C,
    9. Cui Q,
    10. Luo Y,
    11. Fan W,
    12. Chen Y,
    13. Sun Y,
    14. Guo W,
    15. Tan W,
    16. Lin D and
    17. Wu C
    : Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma. Theranostics 10(8): 3488-3502, 2020. PMID: 32206103. DOI: 10.7150/thno.41427
    OpenUrlCrossRefPubMed
  160. ↵
    1. Li G,
    2. Qi HW,
    3. Dong HG,
    4. Bai P,
    5. Sun M and
    6. Liu HY
    : Targeting deubiquitinating enzyme USP26 by microRNA-203 regulates Snail1’s pro-metastatic functions in esophageal cancer. Cancer Cell Int 20: 355, 2020. PMID: 32760222. DOI: 10.1186/s12935-020-01441-2
    OpenUrlCrossRefPubMed
  161. ↵
    1. Stouffs K,
    2. Lissens W,
    3. Tournaye H,
    4. Van Steirteghem A and
    5. Liebaers I
    : Possible role of USP26 in patients with severely impaired spermatogenesis. Eur J Hum Genet 13(3): 336-340, 2005. PMID: 15562280. DOI: 10.1038/sj.ejhg.5201335
    OpenUrlCrossRefPubMed
  162. ↵
    1. Young MJ,
    2. Hsu KC,
    3. Lin TE,
    4. Chang WC and
    5. Hung JJ
    : The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci 26(1): 42, 2019. PMID: 31133011. DOI: 10.1186/s12929-019-0522-0
    OpenUrlCrossRefPubMed
    1. Pal A,
    2. Young MA and
    3. Donato NJ
    : Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res 74(18): 4955-4966, 2020. DOI: 10.1158/0008-5472.CAN-14-1211
    OpenUrlCrossRef
  163. ↵
    1. Liu J,
    2. Shaik S,
    3. Dai X,
    4. Wu Q,
    5. Zhou X,
    6. Wang Z and
    7. Wei W
    : Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta 1855(1): 50-60, 2015. PMID: 25481052. DOI: 10.1016/j.bbcan.2014.11.005
    OpenUrlCrossRefPubMed
  164. ↵
    1. Li L,
    2. Zhou H,
    3. Zhu R and
    4. Liu Z
    : USP26 promotes esophageal squamous cell carcinoma metastasis through stabilizing Snail. Cancer Lett 448: 52-60, 2019. PMID: 30763716. DOI: 10.1016/j.canlet.2019.02.007
    OpenUrlCrossRefPubMed
  165. ↵
    1. Yan S,
    2. Jiang H,
    3. Fang S,
    4. Yin F,
    5. Wang Z,
    6. Jia Y,
    7. Sun X,
    8. Wu S,
    9. Jiang T and
    10. Mao A
    : MicroRNA-340 inhibits esophageal cancer cell growth and invasion by targeting phosphoserine aminotransferase 1. Cell Physiol Biochem 37(1): 375-386, 2015. PMID: 26316084. DOI: 10.1159/000430361
    OpenUrlCrossRefPubMed
  166. ↵
    1. Sun C,
    2. Zhang X,
    3. Chen Y,
    4. Jia Q,
    5. Yang J and
    6. Shu Y
    : MicroRNA-365 suppresses cell growth and invasion in esophageal squamous cell carcinoma by modulating phosphoserine aminotransferase 1. Cancer Manag Res 10: 4581-4590, 2018. PMID: 30410394. DOI: 10.2147/CMAR.S157858
    OpenUrlCrossRefPubMed
  167. ↵
    1. Ravez S,
    2. Spillier Q,
    3. Marteau R,
    4. Feron O and
    5. Frédérick R
    : Challenges and opportunities in the development of serine synthetic pathway inhibitors for cancer therapy. J Med Chem 60(4): 1227-1237, 2017. PMID: 27959531. DOI: 10.1021/acs.jmedchem.6b01167
    OpenUrlCrossRefPubMed
  168. ↵
    1. Liu B,
    2. Jia Y,
    3. Cao Y,
    4. Wu S,
    5. Jiang H,
    6. Sun X,
    7. Ma J,
    8. Yin X,
    9. Mao A and
    10. Shang M
    : Overexpression of phosphoserine aminotransferase 1 (PSAT1) predicts poor prognosis and associates with tumor progression in human esophageal squamous cell carcinoma. Cell Physiol Biochem 39(1): 395-406, 2016. PMID: 27372650. DOI: 10.1159/000445633
    OpenUrlCrossRefPubMed
  169. ↵
    1. Isozaki Y,
    2. Hoshino I,
    3. Akutsu Y,
    4. Hanari N,
    5. Mori M,
    6. Nishimori T,
    7. Murakami K,
    8. Akanuma N,
    9. Takeshita N,
    10. Maruyama T,
    11. Toyozumi T,
    12. Takahashi M,
    13. Suito H and
    14. Matsubara H
    : Usefulness of microRNA 375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma. Int J Oncol 46(3): 1059-1066, 2015. PMID: 25501018. DOI: 10.3892/ijo.2014.2789
    OpenUrlCrossRefPubMed
  170. ↵
    1. Isozaki Y,
    2. Hoshino I,
    3. Nohata N,
    4. Kinoshita T,
    5. Akutsu Y,
    6. Hanari N,
    7. Mori M,
    8. Yoneyama Y,
    9. Akanuma N,
    10. Takeshita N,
    11. Maruyama T,
    12. Seki N,
    13. Nishino N,
    14. Yoshida M and
    15. Matsubara H
    : Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int J Oncol 41(3): 985-994, 2012. PMID: 22752059. DOI: 10.3892/ijo.2012.1537
    OpenUrlCrossRefPubMed
  171. ↵
    1. Zha X,
    2. Wang F,
    3. Wang Y,
    4. He S,
    5. Jing Y,
    6. Wu X and
    7. Zhang H
    : Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 71(1): 13-18, 2011. PMID: 21199794. DOI: 10.1158/0008-5472.CAN-10-1668
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Urbańska K and
    2. Orzechowski A
    : Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int J Mol Sci 20(9): 2085, 2019. PMID: 31035592. DOI: 10.3390/ijms20092085
    OpenUrlCrossRefPubMed
  173. ↵
    1. Wang Z,
    2. Tang ZY,
    3. Yin Z,
    4. Wei YB,
    5. Liu LF,
    6. Yan B,
    7. Zhou KQ,
    8. Nian YQ,
    9. Gao YL and
    10. Yang JR
    : Metadherin regulates epithelial-mesenchymal transition in carcinoma. Onco Targets Ther 9: 2429-2436, 2016. PMID: 27143938. DOI: 10.2147/OTT.S104556
    OpenUrlCrossRefPubMed
  174. ↵
    1. Hu G,
    2. Wei Y and
    3. Kang Y
    : The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 15(18): 5615-5620, 2009. PMID: 19723648. DOI: 10.1158/1078-0432.CCR-09-0049
    OpenUrlAbstract/FREE Full Text
  175. ↵
    1. Yang C,
    2. Zheng S,
    3. Liu Q,
    4. Liu T,
    5. Lu M,
    6. Dai F,
    7. Gao X,
    8. Sheyhidin I and
    9. Lu X
    : Metadherin is required for the proliferation, migration, and invasion of esophageal squamous cell carcinoma and its meta-analysis. Transl Res 166(6): 614-626.e2, 2015. PMID: 26051629. DOI: 10.1016/j.trsl.2015.05.004
    OpenUrlCrossRefPubMed
  176. ↵
    1. Han DL,
    2. Wang LL,
    3. Zhang GF,
    4. Yang WF,
    5. Chai J,
    6. Lin HM,
    7. Fu Z and
    8. Yu JM
    : MiRNA-485-5p, inhibits esophageal cancer cells proliferation and invasion by down-regulating O-linked N-acetylglucosamine transferase. Eur Rev Med Pharmacol Sci 23(7): 2809-2816, 2019. PMID: 31002132. DOI: 10.26355/eurrev_201904_17556
    OpenUrlCrossRefPubMed
  177. ↵
    1. Maynard JC,
    2. Burlingame AL and
    3. Medzihradszky KF
    : Cysteine S-linked N-acetylglucosamine (S-GlcNAcylation), a new post-translational modification in mammals. Mol Cell Proteomics 15(11): 3405-3411, 2016. PMID: 27558639. DOI: 10.1074/mcp.M116.061549
    OpenUrlAbstract/FREE Full Text
  178. ↵
    1. Gorelik A,
    2. Bartual SG,
    3. Borodkin VS,
    4. Varghese J,
    5. Ferenbach AT and
    6. van Aalten DMF
    : Genetic recoding to dissect the roles of site-specific protein O-GlcNAcylation. Nat Struct Mol Biol 26(11): 1071-1077, 2019. PMID: 31695185. DOI: 10.1038/s41594-019-0325-8
    OpenUrlCrossRefPubMed
  179. ↵
    1. Singh JP,
    2. Zhang K,
    3. Wu J and
    4. Yang X
    : O-GlcNAc signaling in cancer metabolism and epigenetics. Cancer Lett 356(2 Pt A): 244-250, 2015. PMID: 24769077. DOI: 10.1016/j.canlet.2014.04.014
    OpenUrlCrossRefPubMed
  180. ↵
    1. Wang Y,
    2. Feng J,
    3. Zang W,
    4. Du Y,
    5. Chen X,
    6. Sun Q,
    7. Dong Z and
    8. Zhao G
    : MiR-499 enhances the cisplatin sensitivity of esophageal carcinoma cell lines by targeting DNA polymerase β. Cell Physiol Biochem 36(4): 1587-1596, 2015. PMID: 26159783. DOI: 10.1159/000430321
    OpenUrlCrossRefPubMed
  181. ↵
    1. Bergoglio V,
    2. Pillaire MJ,
    3. Lacroix-Triki M,
    4. Raynaud-Messina B,
    5. Canitrot Y,
    6. Bieth A,
    7. Garès M,
    8. Wright M,
    9. Delsol G,
    10. Loeb LA,
    11. Cazaux C and
    12. Hoffmann JS
    : Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res 62(12): 3511-3514, 2002. PMID: 12067997.
    OpenUrlAbstract/FREE Full Text
  182. ↵
    1. Goodman MF
    : Error-prone repair DNA polymerases in prokaryotes and eukaryotes. Annu Rev Biochem 71: 17-50, 2002. PMID: 12045089. DOI: 10.1146/annurev.biochem.71.083101.124707
    OpenUrlCrossRefPubMed
  183. ↵
    1. Goellner EM,
    2. Svilar D,
    3. Almeida KH and
    4. Sobol RW
    : Targeting DNA polymerase ß for therapeutic intervention. Curr Mol Pharmacol 5(1): 68-87, 2012. PMID: 22122465.
    OpenUrlPubMed
  184. ↵
    1. Cui XB,
    2. Peng H,
    3. Li RR,
    4. Mu JQ,
    5. Yang L,
    6. Li N,
    7. Liu CX,
    8. Hu JM,
    9. Li SG,
    10. Wei Y,
    11. Laibo-Yin,
    12. Zhou H,
    13. Li F and
    14. Chen YZ
    : MicroRNA-34a functions as a tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh esophageal squamous cell carcinoma. Oncotarget 8(54): 92454-92469, 2017. PMID: 29190930. DOI: 10.18632/oncotarget.21384
    OpenUrlCrossRefPubMed
  185. ↵
    1. Qin Y,
    2. Zhang Y,
    3. Tang Q,
    4. Jin L and
    5. Chen Y
    : SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 49(2): 138-148, 2017. PMID: 28069586. DOI: 10.1093/abbs/gmw127
    OpenUrlCrossRefPubMed
  186. ↵
    1. Rupaimoole R and
    2. Slack FJ
    : MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3): 203-222, 2017. PMID: 28209991. DOI: 10.1038/nrd.2016.246
    OpenUrlCrossRefPubMed
    1. Mollaei H,
    2. Safaralizadeh R and
    3. Rostami Z
    : MicroRNA replacement therapy in cancer. J Cell Physiol 234(8): 12369-12384, 2019. PMID: 30605237. DOI: 10.1002/jcp.28058
    OpenUrlCrossRefPubMed
    1. Forterre A,
    2. Komuro H,
    3. Aminova S and
    4. Harada M
    : A comprehensive review of cancer MicroRNA therapeutic delivery strategies. Cancers (Basel) 12(7): 1852, 2020. PMID: 32660045. DOI: 10.3390/cancers12071852
    OpenUrlCrossRefPubMed
  187. ↵
    1. Karkhane M,
    2. Lashgarian HE,
    3. Hormozi M,
    4. Fallahi S,
    5. Cheraghipour K and
    6. Marzban A
    : Oncogenesis and tumor inhibition by MicroRNAs and its potential therapeutic applications: a systematic review. Microrna 9(3): 198-215, 2020. PMID: 31686643. DOI: 10.2174/2211536608666191104103834
    OpenUrlCrossRefPubMed
  188. ↵
    1. Zhao L,
    2. Zhou S and
    3. Gustafsson JÅ
    : Nuclear receptors: Recent drug discovery for cancer therapies. Endocr Rev 40(5): 1207-1249, 2019. PMID: 30869771. DOI: 10.1210/er.2018-00222
    OpenUrlCrossRefPubMed
    1. Bushweller JH
    : Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer 19(11): 611-624, 2019. PMID: 31511663. DOI: 10.1038/s41568-019-0196-7
    OpenUrlCrossRefPubMed
    1. Lambert M,
    2. Jambon S,
    3. Depauw S and
    4. David-Cordonnier MH
    : Targeting transcription factors for cancer treatment. Molecules 23(6): 1479, 2018. PMID: 29921764. DOI: 10.3390/molecules23061479
    OpenUrlCrossRefPubMed
    1. Bhagwat AS and
    2. Vakoc CR
    : Targeting transcription factors in cancer. Trends Cancer 1(1): 53-65, 2015. PMID: 26645049. DOI: 10.1016/j.trecan.2015.07.001
    OpenUrlCrossRefPubMed
  189. ↵
    1. Shiroma Y,
    2. Takahashi RU,
    3. Yamamoto Y and
    4. Tahara H
    : Targeting DNA binding proteins for cancer therapy. Cancer Sci 111(4): 1058-1064, 2020. PMID: 32073717. DOI: 10.1111/cas.14355
    OpenUrlCrossRefPubMed
  190. ↵
    1. Weyandt JD,
    2. Thompson CB,
    3. Giaccia AJ and
    4. Rathmell WK
    : Metabolic alterations in cancer and their potential as therapeutic targets. Am Soc Clin Oncol Educ Book 37: 825-832, 2017. PMID: 28561705. DOI: 10.1200/EDBK_175561
    OpenUrlCrossRefPubMed
    1. DeBerardinis RJ and
    2. Chandel NS
    : Fundamentals of cancer metabolism. Sci Adv 2(5): e1600200, 2016. PMID: 27386546. DOI: 10.1126/sciadv.1600200
    OpenUrlFREE Full Text
  191. ↵
    1. Vander Heiden MG and
    2. DeBerardinis RJ
    : Understanding the Intersections between Metabolism and Cancer Biology. Cell 168(4): 657-669, 2017. PMID: 28187287. DOI: 10.1016/j.cell.2016.12.039
    OpenUrlCrossRefPubMed
    1. Hashemi A and
    2. Gorji-Bahri G
    : MicroRNA: Promising roles in cancer therapy. Curr Pharm Biotechnol 21(12): 1186-1203, 2020. PMID: 32310047. DOI: 10.2174/1389201021666200420101613
    OpenUrlCrossRefPubMed
  192. ↵
    1. Zhang Y,
    2. Wang Z and
    3. Gemeinhart RA
    : Progress in microRNA delivery. J Control Release 172(3): 962-974, 2013. PMID: 24075926. DOI: 10.1016/j.jconrel.2013.09.015
    OpenUrlCrossRefPubMed
  193. ↵
    1. Jones D
    : Setbacks shadow microRNA therapies in the clinic. Nat Biotechnol 36(10): 909-910, 2018. PMID: 30307922. DOI: 10.1038/nbt1018-909
    OpenUrlCrossRefPubMed
  194. ↵
    1. Anastasiadou E,
    2. Seto AG,
    3. Beatty X,
    4. Hermreck M,
    5. Gilles ME,
    6. Stroopinsky D,
    7. Pinter-Brown LC,
    8. Pestano L,
    9. Marchese C,
    10. Avigan D,
    11. Trivedi P,
    12. Escolar DM,
    13. Jackson AL and
    14. Slack FJ
    : Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res 27(4): 1139-1149, 2021. PMID: 33208342. DOI: 10.1158/1078-0432.CCR-20-3139
    OpenUrlAbstract/FREE Full Text
  195. ↵
    1. Witten L and
    2. Slack FJ
    : miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis 41(1): 2-7, 2020. PMID: 31711135. DOI: 10.1093/carcin/bgz183
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cancer Genomics - Proteomics: 19 (2)
Cancer Genomics & Proteomics
Vol. 19, Issue 2
March-April 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models
ULRICH H. WEIDLE, ADAM NOPORA
Cancer Genomics & Proteomics Mar 2022, 19 (2) 113-129; DOI: 10.21873/cgp.20308

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models
ULRICH H. WEIDLE, ADAM NOPORA
Cancer Genomics & Proteomics Mar 2022, 19 (2) 113-129; DOI: 10.21873/cgp.20308
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MicroRNAs and Cancer
    • miRs Targeting Secreted Factors and Transmembrane Receptors in In Vivo Models
    • miRs Targeting Transcription Factors
    • miRs Targeting Metabolic Enzymes (Figure 3)
    • Additional Targets
    • Concluding Remarks
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Long Non-coding RNAs With In Vitro and In Vivo Efficacy in Preclinical Models of Esophageal Squamous Cell Carcinoma Which Act by a Non-microRNA Sponging Mechanism
  • Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma
  • Circular RNAs With Efficacy in Preclinical In Vitro and In Vivo Models of Esophageal Squamous Cell Carcinoma
Show more Review

Similar Articles

Keywords

  • miR-based target identification
  • miR-related treatment modalities
  • preclinical in vivo models
  • squamous cell esophageal cancer
  • review
Cancer & Genome Proteomics

© 2022 Cancer Genomics & Proteomics

Powered by HighWire